[STUDY_ID_REMOVED]
  InSightec 
 
InSightec CONFIDENTIAL   2 | P a g e  A Phase I Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of 
Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Globus Pallidum Us ing 
the ExAblate Transcranial System  
 
 
The goal of this prospective, one arm, non-randomized, multi-center feasibility study is to 
develop data to evaluate the safety and initial effectiveness of unilateral focused ultrasound 
pallidotomy adjunct to PD medications using this ExAblate Transcranial System in the 
management of dyskinesia symptoms for medication refractory, advanced idiopathic Parkinson ’s 
disease.  
The Indications for Use claim for this system is: management of medication-refractory 
dyskinesia symptoms adjunct to PD medication in subjects with advanced idiopathic Parkinson ’s 
disease. 
 
 
 
 
 
  InSightec 
 
InSightec CONFIDENTIAL   3 | P a g e  TABLE OF CONTENTS 
1 BACKGROUND AND SIGNIFICANCE .............................................................................................  5 
1.1. IDIOPATHIC PARKINSON ’S DISEASE  ..............................................................................................................  5 
1.1.1.  SURGICAL TREATMENTS FOR THE MOTOR SYMPTOMS OF PD .......................................................................  5 
1.1.2.  CONTEMPORARY SURGICAL TREATMENTS FOR PD TREMOR  ........................................................................  6 
1.2. EXABLATE MR  GUIDED FOCUSED ULTRASOUND TREATMENTS  ................................................................ . 8 
1.3. EXABLATE TRANSCRANIAL SYSTEM  ...........................................................................................................  9 
1.4. RISKS ASSOCIATED WITH THE CURRENT STANDARD OF PRACTICE IN STEREOTACTIC BRAIN 
SURGERY /THERAPIES ................................................................................................................................. . 11 
1.4.1.  HEMORRHAGIC SURGICAL COMPLICATIONS  ...............................................................................................  11 
1.4.2.  PLACEMENT ERROR  ....................................................................................................................................  11 
1.4.3.  RISK FROM RF ABLATION  ..........................................................................................................................  11 
1.4.4.  RISK FROM DBS ........................................................................................................................................  12 
1.5. HISTORY OF AND RATIONALE FOR EXABLATE FOR BRAIN SURGERY  ........................................................  12 
1.5.1.  RATIONAL FOR EXABLATE TRANSCRANIAL SYSTEM PALLIDOTOMY FOR THE TREATMENT OF 
MEDICATION -REFRACTORY ADVANCED IDIOPATHIC PD ...........................................................................  13 
1.6. SUMMARY  ..................................................................................................................................................  14 
1.7. CLINICAL EXPERIENCE WITH EXABLATE  ...................................................................................................  15 
1.7.1.  CLINICAL EXABLATE BODY SYSTEM  ........................................................................................................  15 
1.7.1.1.  EXABLATE BODY SYSTEM FOR THE TREATMENT OF UTERINE FIBROI DS ...................................................  15 
1.7.1.1.1.  EXABLATE NEW SOFTWARE VALIDATION (IDE  #G050221) .....................................................................  15 
1.7.1.1.2.  ENHANCED SONICATION PROTOCOL (IDE  #G060017) ..............................................................................  15 
1.7.1.1.3.  ENHANCED SONICATION POST MARKETING STUDY -P040003/S007 ..........................................................  15 
1.7.1.1.4.  VALIDATION OF EXABLATE UF V2 – IDE  G100127. .................................................................................  15 
1.7.1.2.  EXABLATE BODY SYSTEM FOR THE TREATMENT OF BREAST CANCER  ......................................................  16 
1.7.1.2.1.  EXABLATE ABLATION OF BREAST CARCINOMA : CLINICAL STUDY WITH EXCISION  ..................................  16 
1.7.1.2.2.  EXABLATE ABLATION OF BREAST FIBROADENOMA  ..................................................................................  16 
1.7.1.3.  EXABLATE BODY SYSTEM FOR THE TREATMENT OF PROSTATE STUDIES – INVESTIGATIONAL FEASIBILITY 
STUDIES  .....................................................................................................................................................  17 
1.7.1.4.  EXABLATE BODY SYSTEM FOR THE PALLIATIVE TREATMENT OF METASTATIC BONE TUMORS  ................  17 
1.7.1.4.1.  BONE FEASIBILITY STUDY IDE#  G050177 ................................................................................................  17 
1.7.1.4.2.  PIVOTAL BONE METASTASIS STUDY (IDE#  G070022)  – BRIEF OVERVIEW  ...............................................  18 
1.7.1.4.1.  CONFORMAL BONE SYSTEM (CBS)  STUDY SUMMARY – FDA  STUDY : IDE  G 080206 ..............................  18 
1.7.2.  EXABLATE TRANSCRANIAL 4000  SYSTEM  ................................................................................................  18 
1.7.2.1.  EXABLATE TRANSCRANIAL TREATMENT OF BRAIN  ..................................................................................  19 
1.7.2.1.1.  FEASIBILITY STUDY FOR BRAIN TUMOR IDE  # G020182  – EXABLATE TRANSCRANIAL LOW FREQUENCY 
SYSTEM  ......................................................................................................................................................  19 
1.7.2.1.2.  FEASIBILITY STUDY FOR NEUROPATHIC PAIN OUTSIDE THE US  - EXABLATE TRANSCRANIAL  SYSTEM  .. 21 
1.7.2.1.3.  FEASIBILITY STUDY FOR ESSENTIAL TREMOR   IDE  - G100169  - EXABLATE TRANSCRANIAL  SYSTEM  .... 21 
1.7.2.1.1.  PIVOTAL STUDY FOR ESSENTIAL TREMOR  IDE  - G120246  - EXABLATE TRANSCRANIAL  SYSTEM  ..........  21 
1.7.2.1.2.  FEASIBILITY STUDY FOR TREMOR DOMINANT PARKINSON ’S DISEASE  IDE  - G120017  - EXABLATE 
TRANSCRANIAL  SYSTEM  ...........................................................................................................................  22 
1.7.2.1.3.  CE APPROVAL OF THE EXABLATE TRANSCRANIAL MR GFUS  SYSTEM  .....................................................  22 
2 OBJECTIVES ......................................................................................................................................  23 
Efficacy Assessments ...........................................................................................................................................  24 
  InSightec 
 
InSightec CONFIDENTIAL   4 | P a g e  3 DESCRIPTION OF SUBJECT POPULATION ...............................................................................  25 
3.1 SUBJECT SELECTION  ..................................................................................................................................  25 
3.2 SUBJECT ENROLLMENT  ..............................................................................................................................  25 
3.2.1  Inclusion Criteria ...................................................................................................................................  25 
3.2.2  Exclusion Criteria ..................................................................................................................................  26 
4 INVESTIGATION PLAN ...................................................................................................................  28 
4.1 STUDY DESIGN  ..........................................................................................................................................  28 
4.1.1  Pre-Treatment Procedures .....................................................................................................................  28 
4.1.2  Treatment Procedures ............................................................................................................................  31 
4.1.3  Follow- up ...............................................................................................................................................  35 
4.1.4  Study Requirements and Visit Schedule ................................................................................................ . 36 
5 DATA ANALYSIS PLAN ...................................................................................................................  41 
5.1 SAFETY  ......................................................................................................................................................  41 
5.2 EFFICACY  ...................................................................................................................................................  41 
5.3 ADDITIONAL EVALUATIONS .......................................................................................................................  41 
 QUALITY OF LIFE ASSESSMENT WITH PDQ- 39 ...........................................................................................  42 
5.4 STATISTICAL CONSIDERATIONS AND SAMPLE SIZE ....................................................................................  42 
5.5 SUBJECT CONFIDENTIALITY  .......................................................................................................................  42 
6 RISK ANALYSIS ................................................................................................................................ . 42 
6.1 GENERAL PROCEDURE RELATED RISKS .....................................................................................................  43 
6.1.1  Risk of Magnetic Resonance Scanners: ..................................................................................................  43 
6.1.2  Risk of Intravenous (IV) Catheter: .........................................................................................................  43 
6.1.3  Risk of Urinary Catheter: .......................................................................................................................  43 
6.1.4  Risk of Stereotaxic Headframe: ..............................................................................................................  43 
6.1.5  Risks generally associated with pallidotomy procedures .......................................................................  43 
6.1.6  Risks Incidental to the ExAblate Treatment ...........................................................................................  45 
6.1.7  Risks Associated with the ExAblate Treatment ......................................................................................  46 
6.2 ANTICIPATED TREATMENT SIDE EFFECTS FROM EXABLATE  .....................................................................  52 
6.3 ADVERSE REACTIONS AND PRECAUTIONS  ................................................................................................ . 53 
6.4 CRITERIA FOR REMOVAL FROM THE STUDY  ...............................................................................................  54 
6.5 RULES FOR STOPPING THE STUDY  ..............................................................................................................  54 
6.6 ADVERSE EVENT REPORTING  ....................................................................................................................  55 
6.7 DATA SAFETY MONITORING BOARD ..........................................................................................................  56 
7 POTENTIAL BENEFITS ....................................................................................................................  56 
8 MONITORING PLAN ........................................................................................................................  57 
8.1 ELECTRONIC DATA CAPTURE (EDC) .........................................................................................................  57 
9 INVESTIGATOR RESPONSIBILITIES ..........................................................................................  58 
10 APPENDICES ......................................................................................................................................  58 
  InSightec 
 
InSightec CONFIDENTIAL   5 | P a g e   
1 Background and Significance  
1.1. Idiopathic Parkinson’s disease  
Idiopathic Parkinson's disease (PD) is a common, progressive, incurable neurodegenerative 
disease that results in severe disability and eventually, death.[1, 2]  PD affects adults of all races, 
and the incidence tends to increase with age, with estimated lifetime risk estimated at 8.5% and 
7.7% for men and women, respectively.[3, 4]  In PD, the initial pathology is a progressive loss of 
dopaminergic neurons within the substantia nigra in the brainstem that manifests initially as a 
tremor when ~50-70% of nigral dopaminergic cells are lost.[5, 6].  PD tremor is defined as a 
resting tremor of 4-7 Hertz that abolishes with volitional movement[7] and is usually 
accompanied by other motor impairments (tremor, bradykinesia, rigidity and gait impairment).  
PD tremor can also include a postural or action component, but the combination of a pathological 
resting tremor with bradykinesia qualifies as a necessary criteria for the clinical diagnosis of 
idiopathic PD.[8] 
Early in the course of the disease, medical therapy with dopamine replacement is effective at 
minimizing symptoms like tremor and bradykinesia to preserve quality of life, but is often not as 
effective in controling bradykinesia and rigidity.[9].  As the disease progresses, many subject s 
develop medication-refractory PD symptoms, motor fluctuations, and medication-induced 
dyskinesias.[10]  Since higher doses of dopaminergic therapy are associated with drug-induced 
side effects such as drowsiness, nausea, dyskinesias, hallucinations, and orthostatic hypotension, 
subjects may also be unable to tolerate the doses required to control their tremor symptoms.  
Within 10 years, an estimated 59-100% of subject s suffer from medication-related side 
effects.[11-13]  Even with optimization of medical therapy, the amount of time spent with good 
motor control declines in late-stage PD, and it is at this point that subject s typically consider 
surgical options.[14, 15]. 
1.1.1.  Surgical treatments for the motor symptoms of PD 
The earliest surgical interventions for involuntary movements were developed in an effort to 
treat the large number of cases of postencephalic Parkinsonism resulting from the 1920s 
epidemic of influenza.  These procedures, aimed toward the motor system and specifically the 
motor cortex, reduced hyperkinetic symptoms like tremor and chorea, but did little for the 
bradykinesia typically prominent in idiopathic PD.  Excision of the precentral (primary motor) 
cortex effectively alleviated some involuntary movements, but was associated with significant 
morbidity and loss of limb function.  Subtemporal lesioning of the cerebral peduncle 
(pedunculotomy) was developed in order to avoid the epileptic convulsions that accompanied 
cortical resection surgery.   
Lesioning of subcortical structures like the pallidum and thalamus evolved from the famous 
surgical accident of Cooper who inadvertently ligated the anterior choroidal artery during a 
cerebral pedunculotomy procedure, causing a therapeutic pallidal infarction.[16, 17]  Soon 
thereafter, precise stereotactic techniques were applied to pallidotomy procedures to create more 
  InSightec 
 
InSightec CONFIDENTIAL   6 | P a g e  consistent and reproducible lesioning.[18-20]  Stereotactic pallidotomy became recognized as a 
viable treatment for PD with alleviation of bradykinesia and tremor, and the modification of the 
target to the posteroventral pallidum by Leksell was observed to better treat bradykinesia. [21]  
Similarly, ventrolateral thalamotomy, the primary outflow target of the pallidum, was observed 
to improve parkinsonian features and especially tremor. [21-23]  In the 1960s, dopamine 
replacement became available for symptomatic therapy of PD, and surgical procedures 
essentially disappeared for decades. [24]   It was Laitinen who “rediscovered” posteroventral  
pallidotomy decades later as an effective treatment for severe PD symptoms and especially for 
the dyskinetic side effects associated with chronic dopamine replacement. [25]    
PD is rarely unilateral, however, and contralateral lesioning is discouraged because of a lesser 
beneficial effect of the contralateral lesion [26] paired with a higher risk of dysphonia, 
dysarthria, and cognitive dysfunction. [26-28] This resulted in decreased use of pallidotomy, as 
disease progression and medication-related side effects eventually involve both sides of the body 
and warrant bilateral treatment.  Deep brain stimulation became the treatment of choice because 
it can be used bilaterally and is considered reversible.   
Electrical stimulation in basal ganglia targets was welcomed in the late 1980s because of a need 
for improving the safety and reducing side effects of bilateral stereotactic treatments for 
movement disorders.  High frequency electrical stimulation has long been used for acute target 
localization during stereotactic surgery, and chronic stimulation of the sensory thalamus was 
utilized therapeutically to treat neuropathic pain. [29]  In the e arly 1990’s, Siegfried et. al . and 
Benabid et. al ., recognized that chronic thalamic stimulation could be used effectively and 
permanently to suppress tremor, and yet the effects were reversible when the stimulation was 
stopped. [30, 31]  Thus, deep brain stimulation was embraced as a reversible therapy that could 
be titrated toward symptom relief while minimizing negative side effects.  Theoretically, DBS 
would be safer than irreversible, stereotactic ablations.  DBS was soon applied to the pallidum in 
the treatment of Parkinson’s disease [31], and the efficacy of chronic bilateral pallidal DBS was 
observed as comparable to pallidal lesioning. [31-33]  Like the internal segment of the globus 
pallidum, the subthalamic nucleus (STN) was recognized in experimental models of P arkinson’s 
disease to be hyperactive.[34-36]  STN lesions in nonhuman MPTP primates alleviated 
parkinsonian signs, thus paving the way to explore the subthalamus as a potential stereotactic 
target for Parkinson’s d isease.[34, 35, 37-40]  In the 1990’s, bilateral STN DBS in human 
subject s improved PD symptoms in a manner similar to pallidal DBS or pallidal lesioning [6, 41-
43].  Rigorous trials of STN versus globus pallidus interna (GPi) DBS include three randomized, 
double-blind, controlled trials documenting similar motor improvements as tested using UPDRS 
in the nonmedicated state.[44-46].  The only consistent difference between targeting the STN 
and GPi for DBS involves substantial reductions in levodopa medications and more cognitive 
and psychological sequelae with STN DBS.  [6, 44, 45, 47, 48]. 
1.1.2.  Contemporary surgical treatments for PD tremor 
There is no cure or neuroprotective treatment for the neurodegenerative condition of idiopathic 
PD.  Thus, current medical and surgical therapies are aimed toward maximal symptom relief 
with minimal associated side effects or morbidity.  It is now relatively well accepted from 
rigorous clinical trials that surgical procedures like stereotactic ablation of the GPI [49, 50] and 
Deep Brain Stimulation “DBS” [6, 51-53] can provide symptom relief for the dopamine-
  InSightec 
 
InSightec CONFIDENTIAL   7 | P a g e  responsive motor symptoms of PD when medication has failed.  Patients with PD and their 
doctors will seek the easiest and safest treatment assuming that the clinical benefits are 
comparable.  This is the premise for the investigation of focused ultrasound (“FUS”) lesioning in 
the treatment of advanced PD. 
It is generally accepted that a well-placed stereotactic lesion is comparable in its magnitude of 
clinical effect to the high frequency electrical stimulation of the same target.  In fact, prospective 
and retrospective comparative studies with tremor [54-57]and PD [32, 33, 58] have consistently 
documented similar clinical benefits.   
Firstly, Tasker et al. retrospectively reviewed his series of thalamic stimulation and lesioning for 
ET and PD in Toronto with the conclusion that the two were “equally successful,” but that 
symptom recurrence of progression could often be controlled with DBS readjustment as opposed 
to repeat thalamotomy [54].  Prospective comparisons have documented a similar magnitude of 
tremor relief with higher rates of cognitive, dysarthria, and gait morbidity following 
thalamotomy although hardware-associated complications are unique to DBS and the only 
mortality of the series occurred in the stimulation group [55].  Recently, Anderson et al. 
randomized ET patients and noted more improvement in the “regularity” of finger tapping with 
thalamic lesioning then with DBS [57]. 
There are fewer direct comparative studies addressing the motor symptoms of PD besides 
tremor, but unilateral stereotactic radiofrequency pallidotomy seems similar to unilateral pallidal 
DBS.  Both seem to provide approximately 30% reduction (improvement) in the non-medicated 
motor scores of the UPDRS with the strongest effects on contralateral appendicular motor 
symptoms and the reduction of medication-induced dyskinesia [59, 60], R.E. Gross, 
Neurotherapeutics 2008).  Merello et al. prospectively randomized thirteen patients to a 
unilateral pallidal surgery and observed similar UPDRS benefits with perhaps more 
improvement with hand tapping following GPI DBS whereas dyskinesia improved more 
substantially with pallidotomy [61].  Blomsted et al. treated five consecutive patients with 
unilateral pallidotomy followed by contralateral pallidal DBS at a mean of fourteen months 
later[32].  Even though overall mean off UPDRS reductions were as expected at 32%, the degree 
of appendicular improvement in dyskinesia reduction was better contralateral to the lesiont.  
Direct comparisons of subthalamic lesions and stimulation have not been performed like the GPI, 
and bilateral lesioning is discouraged when compared to bilateral DBS due to a higher risk of 
procedural morbidity.   
While surgical lesions in various areas of the motor system have been useful for decades in 
providing some degree of clinical benefit for Parkinson’s patients , the optimal method for 
creating a lesion deep within the brain has not been available, but the ExAblate has the potential 
to create the lesion non-invasively, with real-time visual monitoring, and immediate effect.  With 
the ExAblate system, n on-invasive high-intensity focused ultrasound has been coupled with high 
resolution MRI to provide precise, consistent treatments that can be monitored in real-time.  The 
development of phased array transducers allows for tightly focused treatment volumes and for 
the ability to compensate for distortions by tissue inhomogeneities.[62-64]  The landmark 
advance making the ExAblate Transcranial system possible for neurosurgeons occurred when the 
ability to sonicate precisely through the intact cranium was achieved with phased array 
transducers and acoustic modeling using CT reconstructions of the skull [62-66]  By coupling 
  InSightec 
 
InSightec CONFIDENTIAL   8 | P a g e  high intensity focused ultrasound with MRI, detailed treatment plans can be generated and intra-
procedur al real-time monitoring is available. [67]  Standard MR sequences have been shown to 
reliably predict tissue damage during thermal lesioning with ultrasound.[67, 68]  The precision 
of the technology has already been demonstrated in animal models [69] and is currently being 
investigated in humans with brain tumors [70, 71] , neuropathic pain syndromes [72], and 
essential tremor (IDE#100169).  Unlike stereotactic radiosurgery, the treatment can be monitored 
continuously in real-time with MRI and MR-thermography.[73-79]  Furthermore, clinical testing 
can be performed during low intensity sonication to potentially test the target prior to permanent 
lesioning.  Similarly to the Essential Tremor studies under IDE # G100169; G120246  and 
G120017 , we anticipate that an ExAblate  thermal lesion has a similar safety profile as compared 
to invasive radiofrequency lesioning and will provide years of benefit through reduction of 
contralateral Parkinsonian tremor.   
Ultimately, patients need options that work for their individual needs.  For some patients, the 
burden of management for the DBS device is too cumbersome, time-intensive, and expensive 
with the potential for serious side effects, or may even be contraindicated.  Other treatment 
options, such as pallidotomy, offer similar clinical benefit with less bother, expense, and fewer 
potential side effects.  Neither therapy currently is effective in the last stages of the progressive 
neural degeneration.  However, with the advancement of a precise, minimally invasive method of 
creating a pallidotomy with the ExAblate Transcranial device, pallidotomy may again become an 
equally attractive treatment alternative.   
1.2.  ExAblate MR Guided Focused Ultrasound Treatments  
The ExAblate, using Magnetic Resonance Guided Focused Ultrasound (MRgFUS), is an 
attractive modality for non-invasive, thermal ablation of soft tissue and brain.  The technology 
utilizes the combination of the diagnostic imaging benefits of high-resolution MRI and MR 
thermometry with the therapeutic potency of high-intensity focused ultrasound to deliver a 
precise ablation with many potential clinical applications.  
The treatment begins by acquiring a series of MR images of the target tissue. The physician then 
reviews the images on the ExAblate system workstation, identifies a target volume on the MRI, 
delineates the treatment contours on the images, and reviews the treatment plan.  Therapy 
planning software calculates the parameters required to effectively treat the defined region with 
high intensity, focused ultrasound. During the treatment, an ultrasound transducer generates a 
point of focused ultrasound energy, called a sonication .  The sonication raises the tissue 
temperature within a defined region, causing a thermal coagulation effect.  MR images acquired 
during sonication provide a quantitative, real-time temperature map of the entire field- of-view 
around the target area to confirm the location and intensity of treatment.  The sonication process 
can be repeated at multiple adjacent points and with increased energy to cover a prescribed 
treatment volume such that a coagulated region of tissue results. 
The ExAblate system consists of two units capable of delivering treatment to the body and to the 
brain.  The ExAblate Body system is being investigated in clinical trials for soft tissue tumors, 
[67, 79-83], including breast cancer, prostate cancer, and for the palliation of pain from 
metastatic bone tumors.  It has been approved by the FDA for the treatment of uterine fibroids.   
InSightec 
InSightec CONFIDENTIAL  9 | P a g eSeveral studies are using the ExAblate Transcranial to create a thalamotomy to treat neurologic 
conditions.  The ExAblate advantage over traditional techniques is that it eliminates the need to 
drill into the skull and place an electrode deep within the brain, or alternatively, avoids the use of 
radiation energy while providing immediate clinical response.  A feasibility study has been 
completed in 15 subjects with follow-up through 1 year and a pivotal study is underway.  
Additionally, a feasibility study is underway to evaluate the use of ExAblate Transcranial for the 
treatment of arm tremor in tremor dominant Parkinson’s disease (TDPD).   
The ExAblate Transcranial system has been investigated in the treatment of brain tumors[70, 
71], neuropathic pain[72], and more recently for the treatment of medication-refractory essential 
tremor.  Targeting of other structures or nuclei within the brain can be accomplished quite easily 
with the software of the device.  Tumors can be observed on MR and targeted for ablation.  
Other nuclei of the brain can be stereotactically targeted and ablated in similar fashion. 
This proposed study intends to ablate unilaterally the globus pallidus.  Unilateral pallidotomy 
procedure has been determined by the Movement Disorder Society to be an efficacious treatmen t 
for motor complications associated with Parkinson’s disease in their recent evidence -based 
medicine review update [84]  
1.3. ExAblate Transcranial System  
Ultrasound energy was shown to propagate through intact skull. Transcranial ultrasound has 
been used in pediatric subjects to detect midline shift of the brain.[85]  In adults, blood velocity 
in the basal arteries may be monitored through the intact temporal bone using the Doppler effect. 
[86]  In fact, since the 1950's, the ability of focused ultrasound to produce focal thermal lesions
deep in the brain has been shown in several studies. Animal studies and early clinical studies 
provided encouraging results, showing well-defined tissue coagulation at the focal zone [87-90]. 
Fry et al. showed that a low frequency (around 0.5 MHz) beam could be focused through the 
skull [91, 92].  Their work produced thermal lesions in animal brains through a piece of skull 
immersed in water (bone temperature was not monitored).   
However, ultrasound is strongly attenuated by bone [93].  For this reason, a consensus was 
reached that therapeutic ultrasound cannot be delivered through an intact skull because the 
deflecting effect of the bone; the variable thickness of the skull affects the wave propagation so 
much that the focal spot is lost.  
 High temperatures that are generated in the bone, due to energy absorption, could damage
the scalp, bone and adjacent brain tissue. [94] 
For these reasons, previous focused ultrasound treatments of the brain have involved removal of 
the skull for the sonication pathway [88, 95], resulting in an invasive procedure with additional 
risk and costs.  
The device used in this study, namely the ExAblate Transcranial system addresses the above 
limitations by combining a large phased array, active water-cooling, acoustic aberration 
correction algorithm, and CT data of the skull thickness registration (see component descriptions 
below). 
  InSightec 
 
InSightec CONFIDENTIAL   10 | P a g e  Large Phased Array Transducer.  The system utilizes a large phased array transducer 
that is composed of numerous transducer elements (current system has more than 1000 
elements). It has been shown that large hemispherical phased arrays can deliver adequate 
energy through human skulls to coagulate brain tissue in vivo without excessive 
temperature elevation on the skull surface [96, 97] (see Sections 1.7.2.1  for clinical 
experience with ExAblate transcranial system). 
Active water-cooling . The interface between the subject head and the transducer is filled 
with water, which provides the acoustic path. The system includes a chiller (refrigerating 
unit) that keeps the water chilled at constant temperature so that the skull-bone 
temperature remains within safety limits.  
Acoustic aberration correction algorithm.  Acoustic aberration is created mostly by the 
variations in the bony structure of the skull. The degree of compensation necessary for 
each transducer element is based on predicting the aberration along the acoustic path 
from that element to the target and calculating the relative phase and amplitude correction 
necessary for that element. The result of this compensation is that the acoustic energy 
contribution from each element will arrive at the focal point in phase.  
CT data analysis.  The phase/amplitude correction algorithm, based on ray acoustics 
methods, relies on an input that provides the bone density profile along one or more rays  
between each acoustic element and the target point. This information is extracted from a 
three dimensional CT image of the skull [66]. 
Preliminary clinical data using the ExAblate Transcranial system is now available.  These data 
demonstrate the feasibility of the ExAblate Transcranial thalamotomy procedure as well as the 
initial safety and efficacy in terms of ability to ablate a targeted brain tissue ( see Sections 
1.6.2.1.2 & 1.6.2.1.3 ) . 
The ExAblate Transcranial system combines a focused ultrasound surgery delivery system and a 
conventional diagnostic 1.5 T or 3T MRI scanner. This ExAblate transcranial system provides 
real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The 
latter is achieved by utilizing the unique interactive MRI scan control features of the GE MRI 
system.  
The treatment process concept of this ExAblate Transcranial system is not different from the 
ExAblate body system which is currently in clinical use for some soft tissue applications (see 
Section 1.4).  The treatment begins with a series of standard diagnostic MR images to identify 
the location and shape of the target volume to be treated. The ExAblate computer uses the 
physician's designation of the target volume to plan the best way to cover the target volume with 
small spots called "sonications". The size of these cylindrical lesions depends on sonication 
power and duration.  During the treatment, a specific MR scan, which can be processed to 
identify changes in tissue temperature, provides a thermal map of the treatment volume to 
confirm the therapeutic effect [98]. The thermal map is used to monitor the treatment in progress, 
and confirm that the ablation is proceeding according to plan, thus closing the therapy loop. 
  InSightec 
 
InSightec CONFIDENTIAL   11 | P a g e  The ExAblate Transcranial system operates a helmet-shaped transducer (currently utilizing 
1000+-element phased array transducer) positioned above the subject head. The ExAblate 
Transcranial system also includes means to immobilize the subject ’s head, cool the interface 
water, and software for CT analysis and phase correction computation.  
1.4. Risks associated with the current standard of practice in stereotactic brain 
surgery/therapies.   
1.4.1.  Hemorrhagic surgical complications 
Stereotaxy uses modern, computer-assisted, volumetric imaging techniques to identify targets 
deep in brain in order to advance an electrode to the target.  These stereotactic procedures require 
a scalp incision, a bur hole drilled through the skull, and then penetration of the brain with an 
electrode to reach the target location.  In any open stereotactic procedure, there is a risk of 
hemorrhage associated with insertion of the electrode.  The overall risk of hemorrhagic 
complications is about 2% per electrode insertion, with a risk of permanent neurologic deficit of 
about 1%.  Intraventricular hemorrhages occur in 5% of cases when the electrode traverses the 
lateral ventricular system.  Typically in a stereotactic procedure, the majority of surgical 
complications are associated with traversal of overlying structures such as the cortex or cerebral 
ventricles [99].   
1.4.2.  Placement error 
Target identification in stereotaxy is derived from preoperative CT or MR scans taken with the 
subject in a supine position [100].  The stereotactic surgery is often performed with the subject in 
a semi-recumbent position to minimize the loss of cerebrospinal fluid.  Problems can arise under 
some circumstances [101] such that the brain moves relative to the preoperative scan and the 
calculated coordinates.  This represents a potential source of error in electrode placement.  Any 
deviation in the mechanical geometry of the electrode or the stereotactic apparatus will also 
contribute error which can have a considerable impact on the safety and efficacy of the 
treatment.  Location of the electrode is verified by electrophysiological signal pattern 
recognition, but it cannot be determined whether the electrode is located in the center of the 
nucleus, or in the periphery. 
1.4.3.  Risk from RF ablation 
The electrode used for RF ablations has an RF heated tip.  The peak temperature and the time it 
is maintained define the ultimate size of the lesion.  Temperature drops off smoothly with 
distance from the heated tip, and there is a fairly wide zone of thermal injury that extends for 
several mm around the necrotic core of the lesion.  The damaged tissue will rapidly produce 
edema which can produce local mechanical stress.  The risk of perioperative hemorrhage after 
RF ablation may be higher than after DBS implant [102].  This may be the result of damage to 
blood vessels within the perimeter of the lesion, in areas hot enough to damage the vessel but not 
hot enough to coagulate it.  Mechanical strains on the damaged vessel can develop as the 
necrotic tissue contracts and injured tissue swells, leading to a rupture and intracranial 
hemorrhage.  The ability to produce very sharp temperature gradients at the margins of the 
  InSightec 
 
InSightec CONFIDENTIAL   12 | P a g e  planned lesion would provide a more homogenous lesion and reduce the extent of potentially 
dangerous perilesional edematous regions. 
1.4.4.  Risk from DBS 
DBS therapy has a lower risk of acute perioperative complications than does RF ablation [102].  
It is also adjustable and able to adapt to some degree to symptom progression.  However, DBS 
requires the permanent implantation of at least one multi-contact electrode, a lead extension and 
an implanted pulse generator (IPG).  The implanted DBS hardware is likely permanent for the 
life of the subject.  This means the subject will require surveillance and maintenance of the 
device with replacement of the IPG every 3 to 5 years.  Furthermore, DBS devices produce 
electromagnetic interference and are sensitive to high energy electrical fields which can switch 
them off or even cause a "factory reset" of the device.   
As an implantable device, the DBS hardware problems are not uncommon.  Some reports 
suggest that upwards of 10% of DBS subjects experience some form of hardware failure 
including infection, skin erosion, lead fracture or migration.  Hardware failures can lead to a 
precipitous, unexpected loss of efficacy and invariably requires urgent surgical intervention to 
replace one or more components.   
Implanted DBS hardware is associated with higher risks of infection and skin complications than 
lesioning procedures.  The rate of postoperative infection with DBS surgery has been estimated 
between 3-10%, and such infections typically lead to device explantation if the infection cannot 
be cleared with antibiotics.  Such a scenario leaves the subject without treatment.  Wound 
dehiscence can also occur over the implanted hardware leading to infection as well.  
Even though the DBS technology continues to gain acceptability, its technology remains very 
expensive.  A bilateral GPi implant will incur an institutional cost nearing $100,000 for hardware 
and hospitalization.  Additionally, expensive pulse generator replacements are required every 
three to five years.   
An intervention to inactivate the globus pallidus without requiring the use of implanted hardware 
would be more cost-effective and would avoid the inherent risks associated with chronic 
implants.   
1.5. History of and Rationale for ExAblate for Brain Surgery 
High-intensity focused ultrasound has been used to destroy soft tissue such as neoplasms for 
more than half a century [103].  Until very recently, lesioning brain by sonication has been 
difficult because the overlying skull absorbs most of the sound energy and distorts the 
transmitted acoustic waves.  The landmark advance in the ExAblate Transcranial system for 
neurosurgeons occurred with the ability to sonicate through the intact cranium [62-64, 66].  By 
coupling CT-based phase tuning with the ExAblate Transcranial system, precise and small 
(2x2x3mm) lesions have been produced in deep brain areas while real-time thermal monitoring 
is available to observe the heating caused with each sonication [67].  Standard MR sequences 
have been shown to reliably predict the precise locus of tissue damage during thermal lesioning 
with focused ultrasound [67, 68].  The precision of the ExAblate Transcranial device has already 
been demonstrated in animal models [69] and is currently being investigated in humans with 
  InSightec 
 
InSightec CONFIDENTIAL   13 | P a g e  brain tumors[71], neuropathic pain syndromes[72], essential tremor and Parkin son’s disease .  In 
subjects treated under these protocols to date, no new adverse events have been identified that 
can be solely attributed to the ExAblate Transcranial system.   
This ExAblate Transcranial system was built atop the ExAblate Body system technology, which 
has received FDA and CE approvals for the treatment of uterine fibroids and bone metastasis 
palliation, and is currently being evaluated under various FDA Investigational Device 
Exemptions “IDE” (see Section-1.5  for more details).   
There are many potential advantages for applying ExAblate Transcranial pallidotomy for the 
treatment of medication-refractory, advanced idiopathic PD subjects: 
 The procedure is non-invasive, requiring no incision, no burr hole, and no electrode.  The 
risk of hemorrhagic complication should be reduced, and this non-invasive procedure 
should eliminate the risk of infectious complications.  
 Unlike stereotactic radiosurgery, ExAblate Transcranial system does not use ionizing 
radiation and does not carry a risk of radiation-induced tumorigenesis  
 Unlike radiofrequency ablation, ExAblate Transcranial system thermal lesioning can be 
performed discre tely and accurately.   
 The ExAblate treatment can be monitored in real-time with MRI and MR-thermal 
feedback which permits immediate confirmation of the targeting process.   
 Unlike DBS treatment, there is no implanted hardware, no concern of interference with 
external sources of electromagnetic noise, no need for extensive follow-up for 
programming, and no need for periodic battery replacement.  ExAblate Transcranial 
treatments represent a simpler treatment algorithm for a subject suffering from PD 
tremor.  Hours of clinic time will be saved from DBS device management and 
replacement and health care costs may be greatly reduced.   
1.5.1.  Rational for ExAblate Transcranial System Pallidotomy for the Treatment of 
Medication-Refractory Advanced Idiopathic PD  
Stereotactic radiofrequency lesioning of the thalamus (see Section-1.4.3 above) and the pallidum 
have proven effective for the motor symptoms of PD.  Numerous retrospective case series of 
posteroventral pallidotomy with over six months followup have documented 20-30% 
improvement in PD motor function on the nonmedicated UPDRS.[33, 49, 104-113]  
Randomized, prospective clinical trials of unilateral pallidotomy as compared to best medical 
therapy have confirmed these results [25, 49, 50] with sustained benefits observed  over five and 
ten years. [106, 114]  Unilateral pallidotomy is safe, effective, and recognized as an excellent 
treatment option for a subject suffering from PD. [60]     
 
  InSightec 
 
InSightec CONFIDENTIAL   14 | P a g e  1.6. Summary   
Based on published animal and human studies, we believe ExAblate Transcranial pallidotomy 
can be as safe and as effective as any of the surgical treatments within the currently accepted 
standard of care including RF lesioning and DBS.  A unilateral lesion of the globus pallidus has 
been shown to provide reduction of contralateral motor symptoms in PD.  Using ExAblate 
Transcranial MRgFUS to create the pallidotomy has several potential advantages over current 
therapies including the fact that noninvasive lesioning can be performed in a precise manner with 
continuous clinical and radiographic monitoring.  If the potential of ExAblate Transcranial 
pallidotomy can be realized, it could supplant radiofrequency and radiosurgery techniques, and 
provide a viable alternative procedure for subject s considering DBS, which is invasive, 
uncomfortable, labor-intensive, and expensive.   
 
  InSightec 
 
InSightec CONFIDENTIAL   15 | P a g e   
1.7. Clinical Experience with ExAblate 
1.7.1.  Clinical ExAblate Body System 
1.7.1.1.  ExAblate Body System for the treatment of Uterine Fibroids 
The ExAblate 2000 system received FDA approval for the treatment of Uterine Fibroids in 
October 2004 (PMA # P040003).  Furthermore, this system gained both AMAR authorization 
(Israel Ministry of Health) and CE (European and others) approval for the indication of treating 
Uterine Fibroids. Subsequent studies lead to a software upgrade and an enhanced sonication 
protocol.  A further upgrade to the system to allow the transducer arm 3-dimensional movement 
is currently under IDE investigation as IDE G100127 
1.7.1.1.1.  ExAblate New Software Validation (IDE #G050221) 
This was an FDA-approved study to validate the new ExAblate application software as well as 
the use of the ExAblate system with 3T MR scanners for the treatment of UFs.  This was only a 
safety study.  A total of 40 subjects were treated under this protocol IDE.  The PMA-S was 
approved on February 27, 2007 under P040003/S002. 
1.7.1.1.2.  Enhanced Sonication Protocol (IDE #G060017) 
This was an FDA-approved study to validate the new Enhanced Sonication feature of the 
ExAblate system, a detachable cradle, and several other modifications to the ExAblate 2000 
system.  This was a safety study only.  A total of 50 subjects were treated under this protocol 
IDE.  Following completion of this study, a full PMA supplement was submitted to FDA for 
review and approval [PMA# P040003].  Approval was granted on 12/22/2009 under PMA Supp 
P040003/S006.  The system is marketed under the trade name ExAblate 2000/2100 and is 
indicated for use in treating symptomatic uterine fibroids. 
1.7.1.1.3.  Enhanced Sonication Post Marketing Study-P040003/S007 
InSightec is currently recruiting subjects for a post-market study using the FDA approved 
enhanced sonication feature to demonstrate the safety of the enhanced sonication feature within 
current treatment guidelines of 100% individual fibroid ablation within established serosal and 
sacral treatment margins; this study will enroll 115 subjects and is nearing completion 
(P040003/S007 ). 
1.7.1.1.4.  Validation of ExAblate UF V2 – IDE G100127.  
InSightec is currently recruiting centers and initiating IRB review for study conduct in order to 
gain approval for the ExAblate Model 2100 Type 1.1 (also refer to as ExAblate UF V2).  This 
ExAblate system will be operated with a NEW Clinical Application SW utilizing the added 5 th 
degree of freedom of the transducer (A/P movement) in its overall planning and treatment of the 
uterine fibroids.  This study will enroll 106 subjects under IDE # G 100127. 
  InSightec 
 
InSightec CONFIDENTIAL   16 | P a g e  1.7.1.2.  ExAblate Body System for the Treatment of Breast Cancer  
InSightec conducted FDA approved clinical trials under IDE # G990184 and G990201 to 
evaluate the safety and efficacy of the ExAblate system in the treatment of breast carcinomas 
[115-117].  Both of these studies are now closed.  Currently, InSightec has an FDA conditional 
approval for a new breast cancer phase-2 study (IDE # G060023).  
1.7.1.2.1.  ExAblate Ablation of Breast Carcinoma: Clinical Study with Excision  
InSightec has been conducting FDA approved clinical trials under IDE # G990184 and G990201 
to evaluate the safety and efficacy of the ExAblate system in the ablation of breast carcinomas 
[115-117] .  The study under IDE # G990201 is a closed study with total of 20 subjects treated.  
Histopathological evaluation of the specimen showed that about 97% of the tumor volume was 
within the targeted volume, and about 87% of the tumor tissue within this target volume was 
thermally coagulated.  Of all the subjects treated, only three subjects experienced non-significant 
adverse effects: minor skin burns.  All were managed with over-the-counter medications, and 
resolved within a few days.  All these adverse events occurred prior to the introduction of the 
Active Breast Cooling system.   
The study under IDE # G990184 is a closed study. A total of 36 subjects of the 45 subject s 
granted by this IDE were treated.  Histopathological evaluation of the specimen showed that 
since the introduction of Elongated Sonication Spots and the Active Breast Cooling System 
about 94% of the tumor volume was within the targeted volume, and about 92% of the tumor 
tissue within this target volume was thermally coagulated.  Of all the subjects treated, only three 
subjects experienced non-significant adverse effects: one subject with mild event of redness at 
the ablation site, a second subject with mild event of firmness, and a third subject with a 3rd 
degree skin burn that was due to operator’s targeting error and not due to the device.   
1.7.1.2.2.  ExAblate Ablation of Breast Fibroadenoma  
InSightec conducted a feasibility FDA approved clinical trials under IDE # G930140 to evaluate 
the safety and efficacy of the ExAblate system in the ablation of breast fibroadenoma [81].  
Under this study, a total of 11 subjects were treated.  The results of this study showed that 8 of 
the 11 subjects who had ablations were either partially (>50%) or completely (>90%) successful. 
No adverse effects were reported, except for one case of transient edema in the pectoralis muscle 
two days after therapy.   
Following this feasibility study, InSightec initiated an FDA approved pivotal protocol to study 
ExAblate ablation of Breast Fibroadenoma (IDE # G010225). A total of 110 subject s were 
approved for this trial, and only 27 subjects were treated before the study was closed for 
enrollment due to lack of subjects enrollment.  No unanticipated adverse effects have been 
reported or detected by MRI.  Clinically, acute pain and discomfort were tolerable, and no long-
term complications occurred. 
  InSightec 
 
InSightec CONFIDENTIAL   17 | P a g e  1.7.1.3.  ExAblate Body System for the treatment of Prostate Studies – 
Investigational Feasibility Studies 
Feasibility studies have been performed outside the United States to demonstrate the ability of 
the ExAblate to successfully target the prostate gland and ablate it (Total Gland Ablation – 
TGA).  Additionally studies have been performed using focal therapy to ablate only cancerous 
foci within the prostate and leave the remainder of the gland intact.  The difficulty here is in the 
methods available to identify the cancerous foci.  These cancerous foci are generally not visible 
on MRI or CT, so careful, methodical biopsy mapping with multiple cores (minimum of 12 
cores, commonly 16 cores for larger glands) must be performed in order to identify the portion of 
the gland with the cancer.  In pilot studies with 27 subjects treated to date, the outcomes 
generally have demonstrated a minimal degree of sexual and urinary side effects (except for 
transient obstructive urinary symptoms) unless the cancerous foci involve the neurovascular 
bundles and the conscious decision is made to include them in the treatment region-of-interest.  
Subjects that are eligible for participation are those with slow cancer growth being followed with 
active surveillance or with Gleason score of 6 (3+3) and no more than 2 cancerous foci in two or 
fewer adjacent sectors that would be amenable to ExAblate treatment.  To date, feasibility 
studies are underway in Russia, India, Singapore, Italy, and Canada.  In the United States under 
FDA oversight, InSightec has initiated a feasibility study IDE (G100108) and sites are being 
recruited.  
1.7.1.4.  ExAblate Body System for the Palliative treatment of Metastatic Bone 
Tumors 
First, InSightec performed FDA approved feasibility study[118] of ExAblate ablation of 
metastatic bone tumors under IDE # G050177 in a total of 10 subjects at two (2) study sites 
followed by a pivotal study(PMA # P110039).  We received PMA approval in October 2012. 
1.7.1.4.1.    Bone Feasibility Study IDE# G050177 
This study was designed as a prospective, one arm, non-randomized study to evaluate the safety 
and effectiveness of using ExAblate as a treatment for pain palliation in subjects with metastatic 
bone tumors.  .  Ten subjects were enrolled at two sites.  Nine subjects completed the study; one 
subject could not complete treatment due to limited device accessibility to the lesion.  Enrolled 
subjects had a range of primary cancer types and also a range of targeted lesion locations, 
including the iliac crest, scapula, ischium, and clavicle bone. 
Assessments were performed at baseline, on treatment day, and at follow-up time points of 3 
days, 2 weeks, 1 and 3 months.   
Only 3 mild AEs were reported in the study with no device-related deaths, life-threatening 
injuries or permanent injuries, nor serious adverse events.  All of these events were anticipated 
side effects that were identified in the study protocol as possible treatment-related complications. 
Effectiveness was measured by the level of pain relief (as measured by VAS), decrease in 
analgesics/opiate medication usage, and improved quality of life (as measured by SF-36  A very 
rapid and sustained relief response was observed in subjects’ pain relief  [Baseline:  mean pain 
score was 5.6 ± 1.2 (N=10, score range: 4- 7); Month 3:  the mean pain score 0.4 ± 0.6 (a 93% 
  InSightec 
 
InSightec CONFIDENTIAL   18 | P a g e  decrease from baseline)].  With respect to medication usage, all subjects maintained or decreased 
their medication usage.  Thus, not only did subjects achieve and maintain clinical benefit at 1 
month to 3 months following the ExAblate treatment, but most subjects reported clinically 
meaningful benefit within 3 days of treatment. 
Overall, these results demonstrated the safety and effectiveness of using ExAblate as a treatment 
for pain palliation in subjects with metastatic bone tumors and provided a basis for designing the 
pivotal study.. 
1.7.1.4.2.  Pivotal Bone Metastasis Study (IDE# G070022) – Brief Overview 
This study was designed as a prospective, randomized (3 ExAblate :1 Sham), single-blind 
multicenter sham-controlled clinical trial comparing ExAblate treatment against a Sham 
treatment with follow-up post-treatment to three months.  A total of 148 patients were enrolled 
and treated under this IDE.  This IDE study was reviewed and approved under FDA PMA # 
P110039 ( http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110039a.pdf ).   
The full FDA approved summary may be accessed at: 
http://www.accessdata.fda.gov/cdrh_docs/pdf11/P110039b.pdf  
1.7.1.4.1.  Conformal Bone System (CBS) Study Summary – FDA Study: 
IDE G 080206 
InSightec is currently conducting a study using a modified the transducer configuration in this 
protocol at three sites.  The study is enrolling and to date seven subjects have been enrolled and 
treated with this conformal system.  The study was cleared for 50 subjects.  Although no data is 
available at this time, all the informal information from the participating investigators is that 
there is a very high level of patient acceptance of the device configuration and of the procedure.  
To date, the safety profile continues to be favorable to the ExAblate Bone Metastasis procedure, 
and there were no new event types attributed to the device.   
1.7.2.  ExAblate Transcranial 4000 System  
InSightec has two ExAblate Transcranial systems: mid (650 KHz) and low frequency (200 KHz).  
These 2 systems (medium and low range frequency) serve two different purposes:  
1. Mid frequency: functional discrete lesioning for deep central locations; focal thermal 
lesions  
2. Low frequency: tumor ablation and has wide treatment envelope 
  InSightec 
 
InSightec CONFIDENTIAL   19 | P a g e  These differences are summarized in the following table:  
Table 1:  Summary of main differences between the low and mid frequency 
ExAblate systems  
Low frequency ExAblate Transcranial 
Syste m Mid frequency ExAblate Transcranial 
System  
Enables access to most of brain volume Deep brain targets 
Spot diameter: 4-12mm Spot diameter: 2-6mm 
Low frequency (~220kHz) Medium frequency (~650kHz) 
Supports both standard* and burst** 
sonication regimens Supports standard* sonications only 
*Standard  sonication regimen delivers the required energy in a continuous fashion to 
the target 
**Burst Sonication regimen delivers the energy in a series of bursts (multiple high 
amplitude, short duration with millisecond pauses between energy bursts).  The total 
accumulated energy is the same.  The only difference is the way it is delivered to the 
target . 
 
For the proposed study, the same mid-frequency ExAblate Transcranial system that is being 
investigated for the treatment of Essential Tremor subjects (under IDE # G1) will be used.  The 
system uses the same transducer, ALL clinical features and tools of the current FDA ET IDE 
approved version, subject interface and coupling, etc.  There is no change to the thermal 
modeling, energy delivery, beam forming, nor treatment parameters and guidelines, and 
mitigating steps.  Furthermore, the manufacturing process, device risk analysis, SW and HW 
verification and validation have also remained unchanged. 
1.7.2.1.   ExAblate Transcranial Treatment of Brain 
1.7.2.1.1.  Feasibility Study for Brain Tumor IDE # G020182 – ExAblate 
Transcranial Low Frequency System 
In 2002, the FDA approved an IDE for a feasibility clinical study for the ExAblate Transcranial 
system in the treatment of brain tumors.[70, 71]  The purpose of this study is to evaluate the 
safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through 
intact human skull using the ExAblate system.   
This study was limited to 10 subjects with a newly diagnosed glioma, recurrent glioma, or 
metastatic cancer to the brain for whom surgery was felt to be not indicated by a physician not 
associated with the study.  
For this study, the ExAblate transcranial system was the system that had ~500 elements and 
operated at ~650 KHz.  The treatment of the first 3 subjects showed the following: 
- All 3 subjects tolerated the overall treatment procedure well. 
  InSightec 
 
InSightec CONFIDENTIAL   20 | P a g e  - The system registration and use of CT data allowed for a full determination and 
correction of the variability of subject skull thickness and  density 
- Thermal imaging and its feedback confirmed the initial targeting 
- All 3 subjects were managed with conscious sedation which was sufficient to alleviate 
any potential procedure-related pain.  None of the three subjects experienced pain.  
Adverse events included nausea and lip swelling. 
- Detailed analyses of skull temperature demonstrated temperatures ranging between 1- to-5 
C for at the skull/dura interface for acoustic powers up to 800-Watts.   
- During these 3 treatments, all safety subsystems and monitoring of the device provided 
the intended safety monitoring capabilities. 
- Tthe potential of tissue ablation at the focal point in the tumor were as high as 14C 
corresponding to about 51C.  These findings corroborated the various simulations that 
were performed to show it is indeed possible to increase the acoustic power/energy that 
will induce ablation/coagulation of tissue without significant skull heating. 
The results of these three subject s’ treatments formed the basis to continue w ith the trial and 
implement several changes in the system such as: 
 upgrade the transducer from 512 to 1000 elements 
 change the subject interface to a stereotactic frame to improve immobilization and 
subject comfort. 
 Use of lower frequency, ~220 kHz, with burst sonication regime. 
This was accomplished under IDE # 020182/S04.    
The treatment of the 4th subject was done with upgraded system suing the same safety protocol.. 
Utilizing the burst sonication regime, the designated tumor was completely ablated.  Despite an 
apparently uneventful treatment, this tumor subject died of an intracerebral hemorrhage five days 
after ExAblate. The Study Safety Committee determined the cause of the hemorrhage to be 
unknown but possibly multi-factorial. It was related to the propensity of glioblastomas to bleed, 
exacerbated by radiotherapy, medications and an underlying coagulopathy.    
The neuropathologic findings raised the possibility that pre-existing changes in the vessels, such 
as mineralization and wall thickening, may have rendered those vessels more susceptible to 
damage by ultrasound at the doses or frequencies used.  The Study Safety Committee 
recommended a new exclusion criteria (tumors with a known tendency to bleed, subjects with 
abnormal clotting studies or on drugs known to affect coagulation) and clarification of the 
imaging criteria (target volume maximum size requirement < 2.5 cm diameter, or an 8 cc volume 
- the tumor volume may be larger, as long as true midline shift is < 5 mm and the subject is not 
clinically compromised; definition of midline shift > 5 mm – does not include tumor growth 
across midline).  With these provisos, the Safety Committee recommended continuation of the 
  InSightec 
 
InSightec CONFIDENTIAL   21 | P a g e  study.  The FDA approved the recommendation of the Safety Committee under IDE # 
G020182/S15.  The study has received IRB approval and has been restarted. 
1.7.2.1.2.  Feasibility Study for Neuropathic Pain Outside the US  - ExAblate 
Transcranial  System 
An investigator initiated and sponsored study in the treatment of neuropathic pain was conducted 
at the University Hospital Zurich (Zurich Switzerland) using the InSightec ExAblate 
Transcranial (650 KHz) system.  The study was approved by and performed according to the 
guidelines of the ethics committee of the University and the State of Zurich. 
To date, more than nineteen (19) subjects with chronic, medication-resistant neuropathic pain 
underwent selective central lateral thalamotomy (CLT) using the ExAblate Transcranial 
treatment. Therapy-resistance was defined as occurring when the subject’s  pain was not 
effectively treated by anti-epileptic and anti-depressant analgesic medications.  
For all subjects, the treatment was well tolerated and did not result in any side effects or 
neurological deficits.  The only significant event reported to date from this study is an event of 
neurological deficit, i.e. “ dysmetria (dyscoordination) of the right hand, dysarthria, motor neglect 
and gait disorder”.  This event was reported immediately following the last sonication.  
Furthermore, all symptoms improved significantly 1-hour post treatment.  The full event was 
submitted to the FDA as part of the Essential Tremor IDE submission (IDE # G100169).   
As it was shown in the brain tumor study under IDE G020281, for this study there was no 
clinically significant heating at the skull-brain interface.  The mean brain surface temperature 
was approximately 39° C.  Furthermore, all subjects experienced some level of pain relief during 
the procedure, and at 48 hours after the treatment, subjects reported pain relief ranging from 30 
to 100% (mean = 68%).  Partial results of this study were published in the Annals of Neurology 
Journal .      
1.7.2.1.3.  Feasibility Study for Essential Tremor  IDE - G100169 - ExAblate 
Transcranial  System 
InSightec received FDA approval for a feasibility of ExAblate Transcranial System for unilateral 
thalamotomy in the treatment of Essential Tremor under IDE # G100169.  Total of 15 subject s 
were enrolled and treated at one site.  Subjects have shown a significant improvement in their 
Essential Tremor disease following their treatment with the ExAblate Transcranial device.  
Subjects who completed the study requirements have shown stability of the tremor suppression 
all the way to the end of the study.  The full results of this study were published in the New 
England Journal of Medicine  [119].   
1.7.2.1.1.  Pivotal Study for Essential Tremor  IDE - G120246 - ExAblate 
Transcranial  System 
This is a global, multi-center, randomized, sham-controlled pivotal study to evaluate the safety 
and efficacy of ExAblate Transcranial unilateral thalamotomy for treating medication-refractory 
Essential Tremor.  A total of 72 subjects will be recruited for this study which has recently gotten 
  InSightec 
 
InSightec CONFIDENTIAL   22 | P a g e  underway.  After the last subject completes 1 year follow-up, a Pre-Market Approval submission 
will follow.  
1.7.2.1.2.  Feasibility Study for Tremor Dominant Parkinson’s Disease   IDE - 
G120017 - ExAblate Transcranial  System 
This is a, multi-center, randomized, sham-controlled pivotal study to evaluate the safety and 
efficacy of ExAblate Transcranial unilateral thalamotomy for treating medication-refractory 
Tremor Dominant Parkinson’s Disease.  A total of 30 subjects will be recruited for this study ; 
nineteen have been treated as of this date.  After the last subject completes the study, a final 
clinical report will be written and submitted to FDA. 
 
1.7.2.1.3.  CE Approval of the ExAblate Transcranial MRgFUS System  
In December-2012, InSightec received CE Mark of Conformity approval for the ExAblate Model 
4000 Type 1 for the following Indication of Use: 
Intended use ExAblate 4000 transcranial MR guided focused ultrasound 
(TcMRgFUS) system (type 1) intended for thermal ablation 
of targets in the thalamus, sub thalamus and Pallidum 
regions of the brain. 
Indication for use ExAblate 4000 transcranial MR guided focused ultrasound 
(TcMRgFUS) can be used for the treatments of neurological 
disorders (Essential Tremors, Tremor Dominant Idiopathic 
Parkinson’s Disease –  Unilateral) and Neuropathic pain in 
the brain by heat induced focusing using ultrasound energy 
under full MR planning and thermal imaging control.  
 
  InSightec 
 
InSightec CONFIDENTIAL   23 | P a g e  2 OBJECTIVES  
The proposed study will evaluate the safety, and initial efficacy of using the ExAblate 
Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medic ations in 
subject s who are over 30 years of age and considered medication-refractory with advanced 
idiopathic Parkinson’s disease (PD) .   
Safety : To evaluate the incidence and severity of adverse events (AEs) associated with 
ExAblate Transcranial method of pallidotomy in subjects with medication-refractory, 
advanced idiopathic PD.  
Effectiveness : To determine the level of effectiveness of the ExAblate Transcranial 
pallidotomy to manage the dyskinesia of subjects with medication-refractory, advanced 
idiopath ic PD.   
This study is designed as a prospective, multi-center, single-arm feasibility study; all ExAblate-
treated subjects will be followed up for 24 months.  The primary endpoint measured will be 
safety of unilateral, 3Tesla, ExAblate Transcranial pallidotomy for PD as determined from 
adverse events recorded during the 3 month study period.  Patients are followed till Month 24 for 
long-term safety and preliminary efficacy.  Data generated through Month 3 may be used for 
preparation of a pivotal study protocol. 
Safety  
Safety will be determined by an evaluation of the incidence and severity of device- and 
procedure-related complications from the first treatment day visit through the 3 month post –
treatment time point.  All AEs will be reported and categorized by investigators as definitely, 
probably, possibly, unlikely, or unrelated to the device, pallidotomy procedure, and/or 
Parkinson’s  disease progression.  Alternative treatments for PD subject tremor will also be 
captured should they occur.  Adverse events will be reviewed by a Data Safety Monitoring Board 
at periodic intervals.  Relative safety of the ExAblate Transcranial treatment will be evaluated as 
compared to other methodologies for creating pallidotomy as reported in the literature.   
Effectivene ss   
Efficacy endpoints will include comparison of Baseline to each follow-up visit assessment for:  
 Unified Dyskinesia Rating Scale  
 Off-medication, motor score from the MDS-UPDRS, part III  
 On-medication, motor score from MDS-UPDRS, part III  
 MDS -UPDRS Parts I, II and IV 
 Quality of life assessment with PDQ-39  
 Clinician and Patient Global Impression of Change 
 Patient Treatment Satisfaction 
  InSightec 
 
InSightec CONFIDENTIAL   24 | P a g e   
Baseline and follow-up efficacy assessments of the MDS-UPDRS and Unified Dyskinesia 
Rating Scale will be performed b y the treating neurologist.   
Efficacy Assessments 
The Unified Dyskinesia Rating Scale will be performed at Baseline and at Months 1, 3, 6, 12, 
and 24 while on medication.  The Month 3 measure as compared to Baseline while on 
medication will serve as the primary clinical effectiveness endpoint while the Month 6, 12 and 
24 as compared to Baseline will serve to assess continued durability.    
The new Unified Parkinson’s Disease Rating Scale refined by the Movement Disorders Society 
(MDS-UPDRS) in July 2008 [120] will be performed at Screening, Week 1, Months 1, 3, 6, 12, 
and 24 to assess the patient’s motor symptoms.  E ach treated subject will be examined “ off 
medication ” and “ on medication ”.   
Quality of Life will be assessed using the PDQ-39 at Baseline, Months 3, 6, 12 and 24 will be 
compared to Baseline. These assessments will similarly be made in the on-medication state. 
Additional questionnaires such as the Clinician Global Impression of Change, the Patient Global 
Assessment of Change, and a Patient Satisfaction Questionnaire will be captured during the post-
treatment phase of the study to assess global health status and the satisfaction of a unilateral 
procedure for controlling their disease symptoms.  Where possible, three days of patient diary 
source data (such as http://www.parkinsons.va.gov/resources/motordiary.pdf  ) will be used for 
calculating ON and OFF times for MDS-UPDRS Part IV and UDysRS. 
 
Study Hypothesis  
The purpose of this study is to evaluate the safety and initial clinical effectiveness of ExAblate 
Transcranial unilateral thermal ablation of the globus pallidus of subjects suffering from 
medication-refractory, advanced idiopathic PD. 
Data will be collect ed to establish the basic safety and clinical efficacy of this type of treatment 
as the basis for later studies that will evaluate the full clinical efficacy.  
Case Report Form Data  
The study data will be collected electronically.   This electronic data capture (EDC) system 
complies with the current guidance of 21 CFR Part 11, Electronic Records and Signatures.  
  InSightec 
 
InSightec CONFIDENTIAL   25 | P a g e  3 DESCRIPTION OF SUBJECT POPULATION     
3.1 Subject Selection   
Subjects with confirmed medication-refractory, advanced idiopathic Parkinson’s disease  will be 
eligible for this study.    
Subjects will first be consented (see ICF in Appendix-A ) in the study for a period of 24 months.  
Consented subjects will receive the standard clinical and imaging work-up as part of their study 
baseline requirements.  Subject eligibility will be confirmed independently by two movement 
disorder specialists on the medial team prior to the procedure.   
Up to 200 subjects may be consented in order to qualify twenty (20 ) medication-refractory, 
advanced idiopathic PD subjects at up to four sites who will be treated in this feasibility study. 
All those subjects that were consented and then were found not meeting study requirements will 
be considered as screen failures. See Section-5.4  for the full sample size discussion.  
3.2 Subject Enrollment 
a) Information concerning eligibility for the study may initially be taken from the subject ’s case 
history.  Subjects who are potentially eligible will be invited to participate in this study.  
b) Written informed consent will be obtained from each participating subject prior to performing 
any testing or further study screening.  The subject will be counseled concerning the 
investigational nature of this study, and the risks and possible benefits to participation.  This 
study will utilize a pre-treatment examination and imaging to screen for adequacy of trial 
participation.  Participation is fully voluntary.  
c)  For this study, ALL Inclusion and Exclusion criteria will be reviewed by the Principal 
Investigator and by a separate investigator of the medical team which may be either a 
neurologist, neuroradiologist, or neurotherapist.  The reviewers must be in FULL agreement on 
all aspects of the Inclusion/Exclusion criteria listed below. 
3.2.1 Inclusion Criteria 
1. Men and women, age 30 years and older 
2. Subjects who are able and willing to give informed consent and able to attend all study 
visits through 24 Months 
3. Subjects with a diagnosis of  idiopathic PD by UK Brain Bank Criteria as confirmed by a 
movement disorder neurologist at the s ite 
4. Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor 
subscale in the ON vs OFF medication state. 
5. MDS- UPDRS score of ≥ 30 in the meds OFF condition  
6. Disabling motor complications of PD on optimum medical treatment characterized 
dyskinesia or motor fluctuations (MDS-UPDRS item 4.2 score of 2 or 3  in the meds ON 
condition) 
  InSightec 
 
InSightec CONFIDENTIAL   26 | P a g e  7. Predominant disability from one side of the body. 
8.  Subjects should be on a stable dose of all PD medications for 30 days prior to study 
entry.    
9. Subject is able to communicate sensations during the ExAblate Neuro procedure. 
 
3.2.2 Exclusion Criteria 
1. Hoehn and Yahr stage in the ON medication state of 3 or greater 
2. Presence of other central neurodegenerative disease suspected on neurological 
examination.  These include: multisystem atrophy, progressive supranuclear palsy, 
corticobasal syndrome, dementia with Lewy bodies, and Alzheimer’s disease.    
3. Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic 
medications. 
4. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal 
ganglia 
5. Presence of significant cognitive impairment defined as score ≤ 21 on the Montreal 
Cognitive Assessment (MoCA) or Mattis Dementia Rating Scale of 120 or lower.  
6. Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, 
psychosis, delusions, hallucinations, or suicidal ideation.  Subjects with stable, chronic 
anxiety or depressive disorders may be included provided their medications have been 
stable for at least 60 days prior to study entry and if deemed appropriately managed by 
the site neuropsychologist 
7. Subjects with significant depression as determined following a comprehensive 
assessment by a neuropsychologist.  Significant depression is being defined 
quantitatively as a score of greater than 191 on the Beck Depression Inventory. 
8. Legal incapacity or limited legal capacity as determined by the neuropsychologist  
9. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined 
by the criteria outlined in the DSM-IV as manifested by one (or more) of the following 
occurring within the preceding 12 month period:   
a. Recurrent substance use resulting in a failure to fulfill major role obligations at 
work, school, or home (such as repeated absences or poor work performance 
related to substance use; substance-related absences, suspensions, or expulsions 
from school; or neglect of children or household).  
b. Recurrent substance use in situations in which it is physically hazardous (such as 
driving an automobile or operating a machine when impaired by substance use)  
c. Recurrent substance-related legal problems (such as arrests for substance related 
disorderly conduct)  
                                                           
1 Per 1996 BDI-II Guidelines; Significant depression, such as Moderate and Sev ere depression is scores of 20 and 
above.  http://www.psychcongress.com/saundras-corner/scales-screenersdepression/beck -depression-inventory- ii-
bdi-ii 
  InSightec 
 
InSightec CONFIDENTIAL   27 | P a g e  d. Continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the substance (for 
example, arguments with spouse about consequences of intoxication and physical 
fights).  
10. Subjects with unstable cardiac status including: 
a. Unstable angina pectoris on medication 
b. Subjects with documented myocardial infarction within six months of protocol 
entry 
c. Significant congestive heart failure defined with ejection fraction < 40  
d. Subjects with unstable ventricular arrhythmias  
e. Subjects with atrial arrhythmias that are not rate-controlled 
11. Severe hypertension (diastolic BP > 100 on medication)  
12. Current medical condition resulting in abnormal bleeding and/or coagulopathy 
13. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one 
week of focused ultrasound procedure or drugs known to increase risk or hemorrhage 
(e.g. Avastin) within one month of focused ultrasound procedure  
14. Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: 
platelet count less than 100,000 per cubic millimeter, a documented clinical 
coagulopathy, or INR coagulation studies exceedi ng the institution’s  laboratory standard  
15. Patient with severely impaired renal function with estimated glomerular filtration rate 
<30  mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who 
is on dialysis; 
16. Subjects with standard contraindications for MR imaging such as non-MRI compatible 
implanted metallic devices including cardiac pacemakers, size limitations, etc.  
17. Significant claustrophobia that cannot be managed with mild medication. 
18. Subject who weigh more than the upper weight limit of the MR scanner table and who 
cannot fit into the MR scanner  
19. Subjects who are not able or willing to tolerate the required prolonged stationary supine 
position during treatment.  
20. History of intracranial hemorrhage 
21. History of multiple strokes, or a stroke within past 6 months 
22. Subjects with a history of seizures within the past year 
23. Subjects with brain tumors  
24. Subjects with intracranial aneurysms requiring treatment or arterial venous 
malformations (AVMs) requiring treatment. 
25. Are participating or have participated in another clinical trial in the last 30 days 
26. Any illness that in the investigator's opinion preclude participation in this study.  
27. Subjects unable to communicate with the investigator and staff. 
28. Pregnancy or lactation.  
  InSightec 
 
InSightec CONFIDENTIAL   28 | P a g e  29. All patients with severe premorbid risks [MDS-UPDRS Part II subsection activities of 
daily living scores of a three or four in question 2.1 (speech), question 2.2 (salivation), or 
question 2.3 (swallowing)] will be excluded.  
30. Subjects who have an Overall Skull Density Ratio of less than 0.40 as calculated from the 
screening CT. 
4 INVESTIGATION PLAN 
4.1 Study Design 
This is a multi-center, prospective, open-label feasibility study to evaluate the safety and initial 
clinical effectiveness of unilateral ExAblate Transcranial pallidoto my of medic ation-refractory, 
advanced idiopathic, PD:   
 PD subjects will be targeted with unilateral ExAblate Transcranial MRgFUS to the 
contralateral symptom-dominant side of the globus pallidum, internal segment.   
4.1.1 Pre-Treatment Procedures  
All the activities that are part of the Pre-Treatment Procedure MUST BE performed at 
least 24h prior to the actual treatment procedures of Section-4.1.2.   
1) Subjects with suspected medication-refractory PD will be screened for preliminary eligibility 
for the study. Potential candidates will be offered an Informed Consent to sign prior to 
further evaluation (see Appendix-A  of this protocol for an Informed Consent template).  
Those who accept will be assigned a Subject study number.  
2) A complete medical history will be obtained to determine Subject’s  general health status.   
3) A comprehensive neurological examination will be performed by a neurologist  
4) A Columbia Suicide Severity Rating Scale (Baseline/Screening version) will be obtained.   
5) Determination of symptom dominant side must be made and concurrence with second 
opinion must occur to determine side for ExAblate Transcranial lesioning. 
6) Medications for the treatment of PD will be reviewed.  PD medication dosage should be 
stable and unchanged for at least 30 days prior to entering the study.  During the study, all 
medication changes will be noted and converted to a standard levodopa equivalent.  
Levodopa equivalent usage will be recorded throughout the study.   
7) Once medication stability has been assessed, a full assessment o f Parkinson’s disease will be 
made using the MDS-UPDRS, parts I-IV administered in the off (unmedicated) and on 
(medicated) state.  Dopamine-responsiveness will be determined by the neurologist by 
comparing meds off and on MDS-UPDRS part III, motor subsections.   Dopamine-
responsiveness will be determined by the neurologist by comparing off and on MDS-UPDRS 
part III, motor subsections.  Dopamine responsiveness is defined as at least a 30% 
improvement in on MDS-UPDRS part III motor scores following the administration of 
  InSightec 
 
InSightec CONFIDENTIAL   29 | P a g e  dopaminergic medications.  Medication-refractoriness or medication-induced side effects 
will be determined by the movement disorder neurologist using the MDS-UPDRS and 
Unified Dyskinesia rating scales. 
8) Gait will be assessed using TGUG assessmen t. 
9) Psychological and cognitive assessment will be performed by a neuropsychologist to screen 
for significant cognitive impairment and unstable mood disorders.  See list of tests in 
Appendix B .    
10) Additionally, quality of life and functional assessments will be obtained from PDQ-39. 
11) Visual field testing will per performed by an ophthalmologist for baseline reference.  
12) Blood will be drawn by venipuncture for PT, PTT, CBC including platelets, and creatinine 
13) Women of childbearing age will undergo a urinary Beta-hCG test for pregnancy.  If the test 
is positive, the subject will be excluded from the study.  If the test is negative, she must agree 
to use a barrier contraception method throughout study.  This includes the screening period 
until study completion at 3 Months post treatment.   
14) The subject will have a standard pre-operative visit with an Anesthesiologist or nurse 
anesthetist 
15) Subjects with a prior history of DVT will undergo a DVT screening with lower extremity 
ultrasound.   
16) Pre-treatment imaging will be scheduled prior to treatment. 
1. CT Imaging:  For the purpose of this study, a non-contrast head CT Exam should 
be an Axial scan with bone filter, an image resolution of 512x512, and image 
thickness of 1mm with zero (0) spacing.  This should be performed early in the 
screening process to determine Overall Skull Density Ratio. 
2. MR Imaging:  For the purpose of this study, MR Exams without contrast will be 
performed.   The MR Imaging should include T1, T2, and DTI sequences.  Other 
MR exams may be performed should they be needed. 
17) The head CT and cerebral MRI will be reviewed to assess the scalp, skull, target accessibility 
and brain.   
18) If at any point it is determined that the subject does not  meet all Inclusion and Exclusion 
criteria and cannot be treated, the subject will be removed from the study.  These subject s 
will be considered screen failures, and will not be included in any of the safety or efficacy 
endpoint analyses.  The Screening and Study Exit CRF will be completed with reason for 
screen failure. 
19)  The diagnosis of medication-refractory, advanced idiopathic PD will be confirmed by a 
neurologist specializing in movement disorders.  The neurologist’s assessment must concur 
with the Principal Investigator that the subject meets all inclusion/exclusion criteria to 
continue in the study. 
20) The ExAblate Treatment should be performed no earlier than 24h post consent signing.  
  InSightec 
 
InSightec CONFIDENTIAL   30 | P a g e  21) The subject will be instructed to consume only clear fluids after midnight prior to the 
ExAblate Transcranial pallidotomy, in order to permit the use of immediate general 
anesthesia in case of a treatment complication that may require emergency intervention. 
  InSightec 
 
InSightec CONFIDENTIAL   31 | P a g e   
4.1.2 Treatment Procedures  
WARNING: 
In this study, subject responsiveness and interaction with the treating 
physicians and their clinical team MUST be maintained through the 
full course of the procedure.   
To alleviate the anxiety and discomfort2 that may develop during this 
procedure, mild sedation may be administered so long as the 
subject ’s level of consciousness is not impaired  or compromis ed.  
Subjects must always remain responsive to the physician. 
Subjects will present to the FUS treatment center on the morning of surgery “ off” medication.   
This means that all PD-related medications will be withheld after their last evening dose or at 
least 12 hours prior to the scheduled treatment time and continuing throughout the treatment 
procedure.  Once the ablative treatment is complete, PD medications will immediately be re-
instituted as per the subject ’s usual schedule.  
On the day of the treatment, at least the following clinical team members should be present: 
Neurosurgeon: leads the planning and guidance of the treatment. This person will also 
monitor the neurological performance and clinical status of the subject, and is responsible 
for the overall management of the subject.  He will assess tremor and conduct modified 
neurologic status tests during the procedure.  If the subject is not able to respond to 
evaluation during the treatment, the procedure will stop until contact with the subject can 
be re-established and the neurological status can be evaluated.  
Neuroradiologist: will be accessible to assist in defining the target area and monitoring 
the treatment images for potential adverse reactions such as swelling or bleeding. 
MRI Technician:  will assist in system preparation, and MRI acquisition throughout the 
procedure. 
Subject Monitor (RN or MD):  will monitor vital signs and provide necessary 
medications and support to keep the subject comfortable or stabilize them in the event of 
an emergency. 
The anesthesiologist or nurse anesthetist or neurosurgeon: they will monitor vital signs and 
provide necessary medications to keep the subject comfortable 
                                                           
2 Based upon our experience with the ExAblate treatment of Essential Tremor (ET001 - 
IDE#G100169), subject may develop some degree of anxiety during the course of the procedure.  
Hence for this study, mild sedation may be provided should there be a need to alleviate subject 
anxiety and discomfort.  Subject responsiveness MUST be maintained at all times during the 
procedure.  
  InSightec 
 
InSightec CONFIDENTIAL   32 | P a g e  The overall treatment procedure steps will be performed as follows: 
1. A brief, pre-treatment tremor assessment may be administered upon subject arrival to 
the ExAblate FUS center.  
 
2. An IV line 0.9% sodium chloride will be positioned for the delivery of fluids and any 
medications required during the procedure. Some of the subjects may require a urinary 
catheter to keep the bladder empty during treatment. 
 
3. The subject’s  head will be carefully shaved and examined for pre-existing scalp scars 
or any other scalp lesions. 
 
4. Graduated compression stockings will be worn to prevent deep venous thrombosis in 
the lower limbs.  
 
5. A stereotactic head frame ( as used in stereotactic surgery and radiotherapy) will be 
placed on the subject’s head using a local anesthetic .  The immobilization unit will 
ensure a constant relationship between the target and the transducer during the 
ExAblate treatment.  The pins used to immobilize the head must be MRI compatible. 
 
6. A rubber diaphragm will be attached to the subject’s head.  
 
7. Subject will be positioned supine and headfirst on the MR/ExAblate Transcranial 
therapy table.   
 
8. The half-spherical helmet containing the transducer elements will be positioned 
around the subject's head in the treatment position.   
 
9. The diaphragm will be connected to its component in the transducer to create the 
acoustic coupling system between the ultrasound transducer and the scalp. The helmet 
will then be filled with degassed water.  This volume will be completely filled with 
care to avoid air bubbles between the face of the transducer and the scalp. Through 
active circulation and the cooling system, the water will be maintained chilled 
throughout the procedure to avoid undesired heating of the scalp and skull. 
 
10. MRI compatible, noninvasive blood pressure, systemic arterial oxygen saturation, and 
electrocardiogram equipment will be placed on the subject. 
 
11. A localizer scan (quick T1) and a non-contrast T2-FSE MR scan will be obtained to 
allow further refinement of the position the ExAblate transducer focal point with 
respect to the targeted zone.   
 
12. A series of MR images will be acquired to identify the target area, and plan the actual 
treatment   
1. T1 Weighted imaging exam along at least 2 axes: Axial and Coronal 
2. Other MR imaging series may also be acquired 
  InSightec 
 
InSightec CONFIDENTIAL   33 | P a g e   
13. The neurosurgeon will assure adequate upper extremity mobility in the MR unit to 
visualize tremor during the treatment and will conduct a Baseline assessment in the 
fixed treatment position before the ExAblate procedure begins.   
 
14.  The pre-treatment CT image datasets will be registered to the T1 weighted MR 
images that were just acquired. This image fusion of pre-operative imaging assists in 
the accurate delineation of the target area and determination of a safe sonication 
pathway 
1. The fusion of the CT data is required for the computation of phase correction 
values to correct for skull aberration, and identification of intracranial 
calcifications 
2. Scars of the scalp and intracranial calcifications will be designated as ‘no pass 
regions’ to ensure the ultrasound beam avoids these specific areas.  
 
ExAblate Procedure 
 
1. The treatment volume and plan will be defined by the neurosurgeon.  The ExAblate 
Transcranial system will automatically compute the phase and amplitude corrections 
necessary for the system to produce a focal spot at the desired location.  
 
2. The Subject Monitor will be present throughout the procedure to ensure subject’s  
overall well-being.  The major role is to monitor and control blood pressure to prevent 
hypertension during the procedure.  Under direct supervision of treating medical 
doctor (per local site standard requirements),  the Subject Monitor may also administer 
medications for the management of any side effects experienced by the subject during 
the procedure including nausea.  In any events, the subject must be able to 
communicate during the entire course of ExAblate procedure, and to operate the stop 
sonication button.  Equipment for emergency resuscitation and stabilization will be on 
hand.  In case of such an emergency, the procedure will be immediately terminated 
and the subject will be transferred to the hospital for further care. 
 
3. A central point in the targeted area will be targeted with a low dose, sub-lethal energy 
level sonication to confirm the targeting accuracy on the MR images.  Focal point 
position and/or transducer location will be adjusted as necessary. 
 
4. To enhance the procedure safety and mitigate some of the inherent risks of thermal 
lesioning of brain tissue: 
a. The ExAblate Transcranial pallidotomy will be performed as a series of 
sonications with small increments in power within the designated target 
volume of the internal segment of the globus pallidum (GPi) in the non-
anesthetized subject. 
b. The subject will be examined by the treating physician and his team during & 
after each sonication for neurologic signs and symptoms, evidence of 
symptom suppression, and vision side effects occurring during the procedure.  
  InSightec 
 
InSightec CONFIDENTIAL   34 | P a g e  The treating physician is in direct communication with the patient at all times 
from within the MR suite. 
c. The series of sonications will start with low energy prior to permanent thermal 
ablation.  This is to ensure the planned sonication to be centered on the GPi.  
Low energy sonication will non-destructively warm the target.  The warming 
will be captured by the MR thermometry and the MR thermal images will be 
displayed in real time to the treating physician.  The neurosurgeon will then 
verify that the warming is centered on the anatomic target.  This will allow the 
centering of the eventual permanent thermal lesion in the planned location. 
d. The titration of escalating focal sonications will continue up to full ablation of 
the targeted planned area for ablation.  This would be performed by utilizing 
the full feedback that is provided by the real time MR Thermomet ry.   
5. The ExAblate Transcranial system is equipped with Stop Sonication Buttons:  One for 
the subject to utilize, one for the Assessor, and one for the treating neurosurgeon.  
Hence, in the event of discomfort or pain, the subject will have the ability to abort the 
sonication at any time by activating the Stop Sonication Button.  Once this button is 
activated, the system will instantly stop the energy delivery.  The same thing will 
happen in the event the treating neurosurgeon or the Subject Monitor or Assessor 
activates their button.  After addressing the subject concerns or discomfort, the 
procedure may continue without further delay.   
6. After the ExAblate Transcranial treatment, a series of MR images will be acquired 
within 24 hours to assess the treatment effects:   
a. T1 and T2 Weighted imaging exam along at least 2 axes: Axial and Coronal 
b. DWI (including ADC maps, which allows differentiation between lesion-
cytotoxic edema-low ADC and vasogenic edema around the lesion-high ADC).    
Other MR imaging series may also be acquired. 
c. GRE/SWI 
d. DTI 
e. Other imaging as indicated 
 
It should be noted that in the event new neurological deficits or seizures are 
observed, other imaging modalities (including CT) should be performed 
immediately in addition to neurological and physical examinations. 
7. Once the treatment is complete or otherwise terminated: 
a. Remove the subject from the ExAblate table and remove all monitoring 
equipment, rubber diaphragm, and stereotactic frame. 
b. Document all adverse events including assessment of skin in the vicinity of the 
metallic pin for any superficial events. 
c. Document neurological and physical examinations. 
d. Obtain additional images (including CT) as soon as possible post-procedure if 
warranted by clinical events during the procedure 
  InSightec 
 
InSightec CONFIDENTIAL   35 | P a g e  e. The subject will be transferred to the hospital for recovery and neurological 
observation until the next morning.    
 
The neurosurgeon will evaluate th e subject’s neurological and  symptom status and make a 
decision as to whether or not to discharge the subject.  Subjects who are found to be 
neurologically unstable will remain in the hospital until the neurosurgeon determines it is 
medically indicated to discharge without consideration of the hospitalization constituting a 
serious adverse event.  A postoperative MRI will be obtained prior to discharge from the 
hospital.  
4.1.3 Follow- up  
4.1.3.1  Follow-up for ExAblate-treated Subjects 
Subject follow-up will be completed at 1-Day, 1-Week, and 1, 3, 6, 2 and 24 months for all 
subjects.   
Subjects will be evaluated for general health, neurological changes, and PD symptomology and 
quality of life measurements as well as for device/procedure/PD disease progression- related 
adverse events that may have occurred during the follow-up period.  
The following measurements should be collected at Day 1(before discharge) 
 General physical 
 Neurological exam 
 C-SSRS (Since last visit) 
 Concomitant and PD medications 
 Adverse events 
 Within 24 hours of treatment - MRI with sequences including T1 and T, weighted 
images; DWI (including ADC maps, which allows differentiation between lesion-
cytotoxic edema-low ADC and vasogenic edema around the lesion-high ADC); 
GRE/SWI and DTI.   Additional MRI sequences may be acquired as indicated. 
The following measurements should be collected at Week 1 (office visit) 
 General physical 
 Neurological exam 
 C-SSRS (Since last visit) 
 Concomitant and PD medications 
 Adverse events 
 
The following measurement should be collected at Months 1, 3, 6, 12 and 24 (office visits).   
 General physical  
  InSightec 
 
InSightec CONFIDENTIAL   36 | P a g e   Neurological exam  
 C-SSRS (Since last visit) 
 Visual field assessment will be performed by an opthamologist at Month 3 only. 
 Gait (TGUG) 
 MDS-UPDRS, Parts I and II 
 Off-medication, MDS-UPDRS part III  
 On-medication, MDS-UPDRS part III  
 On Medication MDS-UPDRS, Part IV 
 On medication, Unified Dyskinesia Rating scale  
 Patient Clinical Global Impression of Change 
 Clinician Clinical Global Impression of Change 
 Patient Treatment Satisfaction Questionnaire 
 Neuropsychological testing at 6, 12 and 24 months only 
 Quality of Life PDQ-39 at Months 3, 6, 12 and 24. 
 Concomitant and PD medications at every visit  
 Adverse events at every visit 
 MR Images: DWI (including ADC maps, which allows differentiation between lesion-
cytotoxic edema-low ADC and vasogenic edema around the lesion-high ADC); 
GRE/SWI and DTI at Month 1 and 6 only 
Additional MRI sequences may be acquired as indicated.  
All pre-treatment and post treatment MR images will be sent to the Sponsor and anonymized and 
stored without subject identifiers by study number.   
 
4.1.4 Study Requirements and Visit Schedule  
The table below summarizes the study visit schedule and procedures.  Appropriate case report 
forms for each visit must be completed and entered into the electronic data capture system. 
The post treatment study visits are as follows: 
 1Day,  
 1 Week (i.e. 7days) ± 3 days,  
 1 Month ± 7 days (i.e.  ± 1 week)  
 3 Month ± 14 days (i.e.  ± 2 weeks),  
 6 Months ± 21 days (i.e.  ± 3 weeks) 
  InSightec 
 
InSightec CONFIDENTIAL   37 | P a g e   12 Months ± 21 days (i.e. ± 3 weeks) 
 24 Month  ± 30 days (i.e. ± 1 month) 
 
Table 2.   Schedule of Events  
Procedures 
Screening 
Baseline 
Day 0 
Day 1 
Day 7 
(±3 days) 
Month 1 
(± 7 days) 
Month 3 
(±14 days)  
Month 6-    
(+ 21 days) 
Month 12  
(+ 21 days) 
Month 24  
(+ 30 days) 
Written Consent X          
Eligibility Consensus X          
Demographics, 
Medical History X          
Labs X          
CT  X         
MRI  X X X  X  X   
General Physical Exam X  X X X X X X X X 
Neurological Exam X  X X X X X X X X 
Visual Field Testing  X     X    
C-SSRS X   X X X X X X X 
Gait (TGUG) X     X X X X X 
MDS-UPDRS, 
parts I-II X     X  X  X X X 
On MDS-UPDRS,parts I III  X     X X X X X 
Off MDS-UPDRS,parts I II  X     X  X  X X X 
ON MDS-UPDRS, Part IV  X     X X X X X 
Unified Dyskinesia Rating Scale  X     X X X X X 
Neuropsychological Assessment  X      X X X 
Quality of Life (PDQ- 39)  X     X X X X 
  InSightec 
 
InSightec CONFIDENTIAL   39 | P a g e  Procedures 
Screening 
Baseline 
Day 0 
Day 1 
Day 7 
(±3 days) 
Month 1 
(± 7 days) 
Month 3 
(±14 days)  
Month 6-    
(+ 21 days) 
Month 12  
(+ 21 days) 
Month 24  
(+ 30 days) 
Patient Clinical Global Impression 
of Change     X X X X X X 
Clinician Clinical Global 
Impression of Change     X X X X X X 
Patient Satisfaction Questionnaire      X  X X X 
PD Medications (mg) 
Levodopa equivalents X X X X X X X X X X 
ExAblate Pallidotomy   X        
Adverse Events   X X X X X X X X 
Exit          X 
 
Table 3.  MR Imaging Requirements by Visit. 
Baseline T1, T2, and DTI sequences without contrast  
Other MR exams may be performed should they be needed. 
Treatment “Part of the ExAblate procedure”  
3. A localizer scan (quick T1) and a non-contrast T2-FSE MR scan  
4. T1 Weighted imaging exam along at least 2 axes: Axial and 
Coronal 
5. Other MR imaging series may also be acquired 
Immediately Post-
procedure or within 24 
hours of procedure 1. T1 and T2 Weighted imaging exam along at least 2 axes: Axial 
and Coronal 
2. DWI  
3. GRE/SWI 
4. DTI: The ROI would cover the posterior limb of the internal 
capsule and middle cerebral peduncle. 
5. Other MR imaging series may also be acquired 
Month 1 o T1 and T2 Weighted imaging exam along at least 2 axes: Axial 
and Coronal 
o DWI  
o GRE/SWI 
o DTI: The ROI would cover the posterior limb of the internal 
capsule and middle cerebral peduncle. 
o Other MR imaging series may also be acquired. 
Month 6 o T1 and T2 Weighted imaging exam along at least 2 axes: Axial 
and Coronal 
o DWI  
o GRE/SWI 
o DTI: The ROI would cover the posterior limb of the internal 
capsule and middle cerebral peduncle. 
o Other MR imaging series may also be acquired 
NOTE:  Copies of all imaging (de-identified using subject ID number) will be sent to 
InSightec. 
 
  InSightec 
 
InSightec CONFIDENTIAL   41 | P a g e    
5  DATA ANALYSIS PLAN 
Descriptive statistics will be performed for all outcomes after the last subject has attained 3 
months follow-up. This data may be used to develop a pivotal study.  Additional reports will be 
generated after the last subject has completed 12 months follow-up, and a study completion 
report after the last subject has obtained 24 months follow-up.  For this study, the Safety and 
Effectiveness assessment will be descriptive with no statistical endpoints.  The results will be 
examined and analyzed and used as a basis for determining the nature of future studies.  Formal 
hypothesis testing for efficacy is not proposed for this initial safety and preliminary efficacy trial.     
5.1 Safety 
A Data Safety Monitoring Board (DSMB) will be used to review all AEs on the study. Their role is t o 
evaluate all AE's that occur throughout the study and provide their assessment of the study safety profil e 
as well as their recommendations for the study continuation.  The DSMB recommendations will be 
communicated to the FDA as part of the annual reporting for this proposed IDE study.   
Adverse events will be recorded and categorized according to severity, relationship to procedure and 
relationship to device.  All AEs will be assessed for their relationship to the study device  or procedure. 
Standard Code of Federal Regulation definitions for Serious Adverse Events (SAEs) and Unanticipated 
Adverse Device Effects (UADEs) will be used in assessment of AEs . 
5.2 Efficacy 
The primary efficacy endpoint will be focused on determining the change from baseline of the 
On medication Unified Dyskinesia Rating Scale at Month 3 as assessed by a neurologist.   
5.3 Additional Evaluations 
Additional measures of safety will be obtained during the study.  These secondary measures of 
safety will include evaluations post-treatment which are compared to a baseline assessment.  
These measures include: 
 MR imaging (1 day, 1 and 6 months) 
 Cognitive assessment by a neuropsychologist (6, 12 and 24 months months) for 
comparison of clinically significant changes from baseline; CSSRS assessments at all 
visits 
 Visual field testing  (3 months) 
 Gait assessment (TGUG) at 1, 3, 6, 12 and 24 month 
Secondary efficacy endpoints will include comparison of Baseline to post-treatment assessments 
for:  
 Unified Dyskinesia Rating scale at all other time points 
  InSightec 
 
InSightec CONFIDENTIAL   42 | P a g e   Total MDS-UPDRS (parts I-IV) 
o Off (un-medicated) MDS-UPDRS, part III  
o On (medicated) MDS-UPDRS, part III and Part IV 
 Patient and Clinician Global Impression of Change  
 Patient Treatment Satisfaction 
 Levodopa equivalent medication usage (milligrams) 
 Quality of life assessment with PDQ-39 
The results from the physical and neurological exams will be recorded in the CRFs and reviewed 
for possible adverse events.  
5.4 Statistical Considerations and Sample Size 
This is an open-label feasibility study of 20 subjects to be recruited from a maximum of 5 
centers.  In order to attain 20 qualified subjects, up to 200 subjects may be consented and 
screened for participation.  Subjects found not to qualify will be exited as a screen failure.  For 
this study, a statistica l sample size analysis is not proposed.  All those subjects that were 
consented and then found not meeting study requirements will be considered screen failures  
The Safety and Effectiveness assessment will be descriptive with no statistical endpoints.  Th e 
results will be examined and analyzed and used as a basis for determining the nature of future 
studies.   
5.5 Subject Confidentiality  
Subject confidentiality will be maintained throughout this study, including all publications.  Data 
collected and entered into the CRFs are the property of the study sponsor.  Representatives from 
the study sponsor or authorized sponsor representatives, the Institutional Review Board [121], 
Ethics Committee or other regulatory bodies, funding groups, and the Data Safety Monitoring 
Board (DSMB) may receive copies of the study records and may review medical records related 
to the study.  The Sponsor will seek a Certificate of Confidentiality from FDA for this study. 
6 RISK ANALYSIS 
Worldwide, over 8000 treatments have been performed to date with the MR guided FUS 
ExAblate body system.  Risk analysis for InSightec ExAblate systems/clinical investigations has 
been conducted as part of previously approved FDA IDE submissions (G930140, G990151, 
G990184, G990201, G000203, G010225, G020001, G020182, G050177, and G060023, 
G070022, G080009, G080206, G100127, G100169, P040003 and subsequent supplements, and 
P110039).  This data has been re-examined by the study sponsor and it has been concluded that 
this risk analysis has limited applicability to the proposed clinical investigation.  The key 
consideration here is the fact that this proposed study is conducted with an ExAblate 
Transcranial 4000 system (referred to internally as the Brain system) that is completely different 
  InSightec 
 
InSightec CONFIDENTIAL   43 | P a g e  from the ExAblate 2100 body system.  However, in principle, the body and brain systems have 
the same purpose namely to coagulate soft tissue within the body by means of MR guided high 
intensity focused ultrasound.  Additional risks, new and unique to this study are presented in 
Section- 6.2. 
The potential risks described below will be explained to the subject in the informed consent 
process. 
6.1 General Procedure Related Risks 
6.1.1 Risk of Magnetic Resonance Scanners: 
MRI has no known deleterious biological effects in subjects with no contraindications. The 
incidence of claustrophobia during MRI examinations is approximately 10-15%.  All subject s 
exhibiting claustrophobia will be exited from the study. 
6.1.2 Risk of Intravenous (IV) Catheter: 
There is a potential risk from the IV catheter used during the procedure. Participants can expect a 
small amount of pain and/or bleeding/bruising at the IV site.  There is a small risk of infection.  
This procedure will follow the ‘standard of care’ at the study site.  
6.1.3 Risk of Urinary Catheter:   
There is a potential risk if a urinary catheter is used during the treatment.  Participant may expect 
varying levels of Urinary Tract Infection due to the use of the urinary catheter.  In a differen t 
study for the ExAblate treatment of uterine fibroid (Pivotal study under IDE G020001 that lead 
to PMA approval under PMA # P040003), the incidence of this risk was found not to exceed 
3.7%.  This procedure wi ll follow the “standard of care” at the study site. 
6.1.4 Risk of Stereotaxic Headframe:   
In this study, the Integra Radionics frame will be used for all treatments.  The main part of this 
frame is a metal based ring that serves as a base for the rest of the fixation components.  This 
frame comes with non-metallic posts mounts.  Into the non-metallic post mounts, accompanying 
nylon encapsulated screws with a metallic tip are fitted through the posts.  Only the metal tip of 
the screw is in contact with the patient.  The risk of any skin event at or in the vicinity of the 
metallic tips is mitigated by the fact that the screws outer shell are out of nylon, and therefore 
eliminates any electrical conductivity to the skin.  This is further mitigated by the fact that these 
screws are mounted on the non-metallic posts that links them to the metallic ring.  Hence, the 
Integra frame is actually manufactured and sold with built in mitigating steps aimed at reducing / 
eliminating skin event risks. When the full set up is completed, the metallic ring is NOT in 
contact with the patient.  
6.1.5 Risks generally associated with pallidotomy procedures  
The internal segment of the globus pallidum is intimately associated with the junction of the 
lateral edge of the internal capsule and the superior aspect of the optic tract.  As such, 
complications of pallidotomy procedures are based on these anatomic relationships and 
particularly when the treatment extends beyond the confines of the nucleus or when perilesional 
edema develops.  Additionally, increased morbidity is often recognized with advanced 
  InSightec 
 
InSightec CONFIDENTIAL   44 | P a g e  Parkinson’s disease as patients typically present at the time of surgery at a later age and with 
more associated co-morbidities.  The overall rate of permanent adverse event following 
pallidotomy procedures ranges from 3.6 to 14% as reported from our literature review.  These 
are permanent adverse events and the rate of transient adverse events is obviously higher and 
subject to AE reporting and publication bias.  The morbidity and mortality of unilateral 
radiofrequency pallidotomy for the trea tment of Parkinson’s disease is summarized below:  
Table-4 .  Morbidity associated with stereotactic radiofrequency pallidotomy  
 
 Retrospective 
series1 
(N=1959) Prospective 
series2 (N=334) Single 
institution3 
(N=884) 
Mortality 0.4 1.2  
Symptomatic ICH 1.7 3.9 2.7 
Permanent AE 14 13.8 3.6 
    
Hemiparesis 0.9 (1.6) 2.1 1.4 
Facial weakness 1.3 (3.7)  2.4 
Dysarthria 3.2   
2.6 Hypophonia 1.3  
Dysphagia 1.2  
    
Visual field deficit 1.5 (2) 2.4 2.1 
Perioperative 
confusion (~10) (3.9) (6.2) 
Infection 
(meningitis/abscess) < 0.5  0.2 
All results are presented as percentages (%).  Transient effects are presented in ( ).   
1. A Alkhani and AM Lozano.   JNS 94:43-49, 2001 
2. RM deBie, et al.  Neurology 58:1008-12, 2002 
3. Y Higuchi, et al.  Neurosurgery 52:558-71, 2003  
 
The mortality  rate with surgical radiofrequency pallidotomy ranges from 0.4 to 1.2%, and 
primarily occurs from intracerebral hemorrhage.  Symptomatic intracerebral hemorrhage  with 
stereotactic procedures has been estimated to range from 1 to 2%, and may be slightly higher 
with pallidotomy procedures which have been reported in large series to almost 4%.  
Intracerebral hemorrhage with pallidotomy might occur in a slightly higher fashion with 
microelectrode-guided procedures where additional electrode penetrations are required.  In order 
to mitigate the risk for intracerebral bleeding, patients with severe hypertension will be excluded 
from trial participation, and normotension will be maintained throughout all procedures. 
Additionally, delayed ischemic infarction  has been observed in pallidotomy procedures.  The 
occurrence of this complication seems unique to lesioning of the globus pallidum.  Three cases 
were recognized in fifty pallidotomy procedures, and these cases occurred in patients with a 
significant history of vasculopathy identified either clinically or radiographically  (J Y Lim, JNS 
1997).  These ischemic events occurred in a delayed fashion at 10, 51, and 117 days following 
  InSightec 
 
InSightec CONFIDENTIAL   45 | P a g e  the procedure.  It is postulated that such an occurrence results from damage to the perforating of 
vessels of the pallidum. 
Hemiparesis  contralateral to pallidotomy is likely the most significant morbidity associated with 
the procedure.  This typically relates to the involvement of the motor fibers in the internal 
capsule, and has been reported with an incidence of about 2%.  To reduce the risk for 
postoperative weakness following focused ultrasound pallidotomy, an event invariably related to 
extension of the lesion medially into the internal capsule, patients will be awake during the 
procedure such that intraprocedural clinical testing of their strength and motor condition can be 
performed after each sonication.  We intend to begin sonications at a low acoustic energy and 
gradually titrate the treatment towards a therapeutic and ablative energy level only as tolerated 
by the patient. 
Facial weakness  has been observed more frequently and is likely attributed to the somatotopic 
organization of the corticobulbar fibers near the pallidal target.  Dysarthria, hypophonia, and 
dysphagia are similar side effects of pallidotomy procedures likely relating to the same 
corticobulbar fiber projections that are immediately medial to the ventral most aspects of the 
pallidum.  In order to reduce the risks for these, we will exclude all patients with severe 
premorbid risks as determined from the UDRS Part II subsection: activities of daily living.  
Those scoring a three or four in question 5 (speech), question 6 (salivation), or question 7 
(swallowing) will be excluded. 
Visual field deficits  have been recognized because of the relationship of the optic tract below 
the internal segment of the globus pallidum.  Over time, this complication has diminished with 
surgical recognition and intraprocedural testing during open stereotactic surgery to mitigate the 
risk of optic tract injury.  We anticipate that the incidence of visual field deficit in this clinical 
trial of focused ultrasound pallidotomy may be slightly higher than that reported in the literature.  
We intend to perform comprehensive visual field assessments before and after the procedure.  
Many of the studies reporting visual field outcomes did so only by clinical assessment by a 
neurologist or neurosurgeon.  Very few studies document the rate of visual field change with 
quantitative visual field and ophthalmologic assessment.  It is known from pallidotomy and 
hippocampectomy procedures that a small visual field deficit can occur and is frequently 
asymptomatic. 
Perioperative confusion  has frequently been observed following pallidotomy procedures, but 
fortunately this tends to be transient.   The risk of this almost certainly increases with older age 
and more advanced disease.  In order to mitigate the risks of perioperative confusion, all patients 
will undergo preoperative neuropsychological assessment to gage their cognitive reserve and 
ability to tolerate unilateral palatal lesioning. 
Infection  has been rarely observed with pallidal lesioning and certainly with less frequency than 
occurs with pallidal stimulation.  We anticipate a similarly low risk for meningitis or brain 
abscess with transcranial focused ultrasound pallidotomy as there is no incision required for the 
procedure. 
6.1.6 Risks Incidental to the ExAblate Treatment 
There is a potential risk to the subject of deep venous thrombosis from lying in a supine position 
for 3 to 4 hours, but this risk is substantially mitigated by the avoidance of sedative medications.   
  InSightec 
 
InSightec CONFIDENTIAL   46 | P a g e  The risk to the subject from lying still for this treatment should be no greater than that of lying 
still for any other reason.  Subjects will be provided compression stockings, as described above 
(Section 4.3), for use during treatment and are able to move their lower extremities during the 
treatment.  DVT screening will be performed at the discretion of the primary treatment team for 
any subject deemed to be at a high risk for thrombosis.   
There is a risk that the subject may experience a sore neck or back, or discomfort / fatigue from 
lying in the same position for a long time during the treatment.   
6.1.7 Risks Associated with the ExAblate Treatment 
All efforts are undertaken to reduce risk related to the ExAblate treatment.  The following 
mitigations are in place for all procedures: 
1. First, the procedure is performed in the MR scanner. During the treatment MR images will be 
acquired. Using specific scanning sequences and a rapid post-processing program, changes in 
temperature can be detected, and a thermal map of the brain generated. This thermal map will 
reveal any potentially dangerous elevations in temperature. 
2. Second, study personnel can regularly assess cognitive and motor function throughout the 
procedure (i.e.: after each sonication) as well as general neurological function. This will help 
to reveal any indication that tissue damage may be occurring along the beam paths. 
3. Subjects are asked to relay all sensations (i.e., disorientation/dizziness, pain, numbness, etc) 
occurring during the procedure to the circulating staff so that adjustments can be made to 
accommodate modifications to the treatment plan or extend time between sonications. 
4. Third, MR-compatible pulse oximeter, blood pressure cuff, and EKG monitor will be 
monitored throughout the procedure. This information will permit detection of tissue 
damage, edema, or bleeding, if brain or blood vessels along the beam paths are injured by 
heat. 
5. Finally, the subject, Subject Monitor and Assessor, and the neurosurgeon will each have a 
stop sonication button that can instantaneously interrupt the energy delivery at any time. The 
subject is given a stop sonication button in case aberrant tissue heating causes any 
compromise to speech, word finding, or other communication difficulties. The subject will be 
instructed prior to the proceeding that they should use the stop sonication button any time 
they feel excessive pain, discomfort, disorientation or any other unusual sensation. The 
neurosurgeon, Subject Monitor and Assessor, have stop sonication buttons so that if there is 
any sign of neurological change, the energy delivery can be immediately stopped and the 
subject carefully evaluated. Temporary interruption of energy delivery will in no way 
compromise the potential for therapeutic benefit to the subject. Following subject evaluation 
treatment can resume without delay   
The following risks may be associated with the ExAblate Transcranial thermal ablation 
procedure: 
1. Pain and/or discomfort – There is a risk of discomfort to the subject caused by heating of 
tissue.  Focused ultrasound therapy involves precisely controlled pulses of thermal energy 
resulting in tissue coagulation (typically 55-65°C for several seconds) in small tissue 
  InSightec 
 
InSightec CONFIDENTIAL   47 | P a g e  volumes. This induces thermal coagulation of the targeted soft tissue.  The energy 
intensity at the level of the skin away from the pin sites is quite low and sonication 
through scar tissue should be avoided..  The subject may experience both a cold sensation 
from the active cooling circulation of water within the rubber diaphragm as well as a rise 
in temperature in the skull which should be kept to below pain level by the active 
cooling. Because the focal point of the beam will be > 2.5 cm from the dura and there are 
no pain receptors in the brain, there should be no pain associated with ablation, itself. 
The subject will be in constant verbal contact with the neurosurgeon and appropriate 
action can be taken in the event that a subject does experience pain discomfort. Remedies 
could involve lowering energy levels, or increasing the time interval between consecutive 
treatment pulses. The subject also has the ability to abort the sonication at any time by 
activating a handheld cut off circuit (i.e., stop sonication button). 
See also Risk 7c regarding heating of the dura mater and the meninges. 
2. Headache – The subject may experience a headache during or after the procedure which 
may be related to the pin site, slight swelling around the ablated brain tissue, or a reaction 
to the contrast media and should be transient. 
3. Disorientation, light-headedness, dizziness, unsteadiness, nausea/vomiting:  There is a 
potential risk that the subject will have sensations of light-headedness, dizziness, 
unsteadiness or even nausea/vomiting.  Based on the current data, these events should be 
transient and resolve within a day or so. 
4. Occurrences of transient numbness, tingling, eye twitch, hyperesthesia and/or paresthesia 
of the scalp, face and upper extremity have been reported in subjects undergoing Vim 
ablation for essential tremor.  These generally are transient are resolved within minutes to 
one day.  One paresthesia lasted for 4 days, one scalp numbness lasted 2.5 months.   
5. BBB disruption, edema, swelling, hemorrhage or stroke: There is a potential risk of 
hemorrhage during ExAblate procedure 
a. At the focal point or targeted area -  In ExAblate thermal ablation, the high 
temperature at the focal point results in immediate protein denaturation and 
coagulative necrosis. This should be expected to rapidly stop any bleeding that 
might occur in the capillary bed and within small vessels. 
b. Outside and remote to the targeted area.. Alternatively, there could be a disruption 
of the Blood Brain Barrier (BBB) which would allow blood to seep out of the 
cranial blood vessels into the brain tissue.  These events may theoretically occur 
due to heating effects (i.e. secondary hot spots) and or to the pressure wave of the 
ultrasound beam.  To address the risks due to pressure waves of the ultrasound 
beam path, the system has been designed to be well below the “pressure wave 
threshold” that may trigger events of this nature.   
In all cases, thermal and regular imaging will be continuously assessed during the procedure.  
Finally, the subject(s) is continuously monitored during the ablation procedure for any 
  InSightec 
 
InSightec CONFIDENTIAL   48 | P a g e  change in condition.  Also, a set of MR images are collected immediately post procedure to 
evaluate the status of the lesion and surrounding tissues. 
6. Imprecise focal point and ablation of tissue outside of target. There is a risk of imprecise 
targeting of the focal point, and ablation of an area of tissue outside the planned treatment 
volume. If this occurred it is possible that serious neurological deficit or even death could 
result. To limit the risk of this occurring, the treatment process includes a mandatory 
verification step that requires the operator to first check the alignment of the subject 
anatomy, the focal point of the transducer and the MR imaging system.  This procedure, 
done while the subject is in position for treatment, uses a very low energy sonication to 
confirm of the alignment of the focal point and the targeted treatment point in all three 
axes. For each sonication delivered during treatment, the operator gets continuous 
feedback on the position of the intended treatment point superimposed on the thermal 
dosimetry image and can make corrections where required.   
Careful monitoring must be performed to ensure that the location, size, and shape of the 
sonications in three planes (2 views) as well as the temperature of the ablative 
sonication(s) do not extend outside of the target region.  Shaping of the sonication may be 
performed by turning off some of the array transducers.  Biofeedback from the subject 
after each sonication performed at the lower temperatures will guide the placement of the 
sonication so as to help prevent unwanted side effects.  
At any point in the treatment process this low-power verification of the localization may 
be repeated prior to full power sonication. 
7. Subject movement during the procedure that causes focal point to move/change location 
– There is a risk associated with subject motion during a sonication or between 
sonications. This could cause a movement of the tissue relative to the planned treatment 
volume on the system, and in extreme cases could result in the treatment of a point 
outside the planned treatment volume.  Also, because the skull functions as a defocusing 
lens, the phase correction map computed for the target spot will become ineffective if the 
subject moves.  To prevent or minimize this risk, there are several precautions taken to 
prevent motion, and to detect it, if it occurs:   
a. During subject positioning every effort will be made to make the subject 
comfortable and the subject will be educated as to the importance of maintaining 
their position during the treatment.  
b. The subject will be placed in a head immobilization unit based on a stereotactic 
frame. This technology has been effective in preventing movement in stereotactic 
neurosurgery, and has been adapted and modified to the specification of the 
ExAblate.  The transducer and the immobilizer are locked together so that the 
transducer moves with the frame. 
c. The system is designed to detect motion and will abort a sonication if  motion 
occurs during the sonication and will indicate that motion has been detected prior 
to the next sonication being performed. 
  InSightec 
 
InSightec CONFIDENTIAL   49 | P a g e  d. One or more members of the medical team will be in the room throughout the 
sonication to monitor the subjects' medical status and comfort.  Hence, subject 
motion will also be monitored. 
8. Risk of cavitation - There is a risk of cavitation in the tissue at the focal point. Cavitation 
is the collapse of rapidly developed gas bubbles at the focal point due an extreme 
intensity of ultrasound excitation. This rapid collapse could cause high pressure, shock 
waves, and high temperatures. However, we believe that through proper system design 
and careful selection of system operation envelope, there is a very minimal risk that 
cavitation could occur during a treatment, even in the event of user error. We have 
developed an automated treatment planner that takes as its input the targeted ablation area 
depth in tissue, focal volume and tissue absorption, and based on pre-set safe operating 
limits selects sonication parameters that will keep the intensity of ultrasound excitation 
well below the intensity levels that could cause cavitation. 
9. Risk related to sonication pathway - There is the risk that the tissue along the path to the 
target (scalp, skull, dura, brain, etc) could become heated to the point where tissue-
damage might occur which could result in significant neurological damage or even death.  
This heating could be caused by direct improper treatment targeting, irregularities on the 
skin surface (e.g.: scars), treatment of a volume of tissue too close to the skin or bone, 
energy absorption by the bone, or the conduction of sufficient heat to cause a burn. The 
heating in the energy pass zone is always monitored and an additional cooling time can 
be administered when elevated temperatures are detected.  Below are some possible risks 
related to the sonication pathway through different tissues in the head:. . 
a. Skin burn  is a potential risk due to improper acoustic coupling. There ha ve been 
no cases of skin burn in all ExAblate transcranial treatments to date.  The 
treatment set-up process includes filling the gap between the ultrasound 
transducer and the skull with a water-filled membrane to provide acoustic 
coupling. There is a possibility of small air bubbles remaining attached to the 
skin.  These could cause a small focal hot spot and cause local pain or a burn to 
the scalp. The active cooling mechanism unique to this system is designed to 
reduce the risk of skin burns and improve subject comfort.  In previous studies, 
ExAblate treatments have caused burns of the skin using the ExAblate Body 
system. To minimize this risk, the scalp will be carefully shaved, and scars or 
other irregularities (e.g. eczema) will be kept outside the treatment pathway. 
Subjects with remarkable atrophy and poor healing capacity of the scalp (> 30% 
of the skull area traversed by the sonication pathway) will be excluded from this 
study. 
The subject will be in constant verbal contact with the neurosurgeon and 
appropriate action can be taken in the event that a subject does experience pain 
discomfort. Remedies could involve lowering energy levels, or increasing the 
time interval between consecutive treatment pulses. The subject also has the 
ability to abort the sonication at any time by activating a handheld cut off circuit 
(i.e., stop sonication button). 
  InSightec 
 
InSightec CONFIDENTIAL   50 | P a g e  b. Skull and air-filled spaces:  In the treatment planning, air-filled spaces (frontal, 
ethmoid, sphenoid sinus, mastoid) inside the skull are identified in bone window 
CT images and kept outside the pathway.  Should the operator not identify all air 
filled cavities on the treatment path, sonication through these areas could cause 
heating and result in burn of the tissue lining the cavity.  Operators are trained to 
avoid these sonication pathways by marking their existence on the CT scans. 
Other irregularities of the skull, which might scatter the acoustic energy, are 
compensated for in the system. Skull may become heated by absorbing more 
acoustic energy than normal soft tissue. The skull cannot sense pain but the 
overlying soft tissues may sense pain if the bone becomes heated. MRI 
thermometry at 1.5 T is able to detect changes of  ±3 Celsius in soft tissues [122]. 
Possible heat transfer from the skull bone to the brain by successive sonications is 
monitored by MRI thermometry of the cortex and white matter. The sonication 
duration and energy levels, and the cooling times between the sonications are 
adjusted so that the focus in the target tissue is heated while allowing other tissue 
to cool down between sonications. Local bone damage is unlikely because the 
active cooling mechanism system is designed to keep the bone temperature below 
a temperature that can damage it.  Based on the data acquired to date and 
reviewed by FDA under G020182/S04, the average temperature rise at the skull 
level ranges between 1° to 5° Celsius.  Hence, this active cooling strategy should 
continue to provide the safety needed.  
c. Dura, meningeal arteries and venous sinuses:  The dura adjacent to the skull 
may absorb heat if the bone becomes heated. Dura itself may sense pain and the 
main branches of the arteries are sensitive to heat. The meningeal arteries can 
generally be avoided in the treatment planning as their grooves in the skull are 
visible in 3D-CT. Local necrosis of the dura is unlikely, and were it to happen, it 
would not cause cerebrospinal fluid leakage. The venous sinuses between the two 
leaves of the dura, the sagittal sinus, the straight sinus and the transverse sinus 
may be in the sonication pathway. Their heating will be avoided by the active 
cooling sub system. The sigmoid sinus and the cavernous sinus will be kept 
outside the pathway due to their proximity to the skull base and cranial nerves, 
respectively.  
d. Subarachnoid space:  Cerebrospinal fluid in the thin subarachnoid space between 
the dura and the cortex could possibly transfer heat from bone to the cortex.  
There is no specific risk to the CSF itself becoming heated.   Because it can flow 
within the subarachnoid space, this can serve as another mechanism to prevent 
local hot spots next to the skull.  
e. Cortex:  In previous studies, ExAblate thermal ablation of deep foci in the rabbit 
brain there was no detectable heating of the cortex on MRI or evidence of opening 
of the blood-brain-barrier elsewhere than at the focus of the beam.  Elevated 
temperature in the eloquent cortical areas (motor, sensory, visual, auditory, 
speech) might cause neurological deficits or seizures Temperatures in the 
eloquent areas will be monitored by MRI throughout the procedure and the 
  InSightec 
 
InSightec CONFIDENTIAL   51 | P a g e  cooling time between sonications will be increased if unacceptable thermal 
buildup is detected. 
f. Brain, cranial nerves and cerebral arteries:  In this study the treatment path will 
avoid cranial nerves and major cerebral arteries.  Operators are trained to mark 
them on the MR for the purpose of avoidance during sonication. 
g. Target ablation and the adjacent brain tissue:   Thermal lesioning for the 
treatment of Parkinson’s Disease  through pallidotomy may carry some risks in 
particular to the internal capsule, ventral posterolateral nucleus of the thalamus.  
To mitigate these risks, the ExAblate treatment will be performed in small 
incremental sonications within the designated target volume in the un-
anesthetized subject.. The subject will be examined by the Subject Assessor after 
each sonication for evidence of symptom suppression or clinical side effect.  The 
titration of escalating focal sonications will start from well before evidence of 
thermal heat is detect by MR thermometry and will continue until clinical 
symptom suppression. This procedure will allow re-adjusting the targeting based 
on real time feedback from intra-procedure examination.  This process is designed 
to enhance the procedure safety and minimize the potential adverse events that 
may be encountered in this study.  
h. Micro-calcification :  The subject population of this study may have some level of 
micro- calcification present in the brain tissue.  Given calcium’s higher absorption 
of ultrasound energy, its presence may create additional heating effect along the 
beam path.  This risk is mitigated by utilizing the CT data (to localize the calcified 
areas) and the various tools of the ExAblate system to delineate these areas so that 
the beam is blocked from passing through these calcified areas.   
i. Secondary Hot Spots :  Theoretically speaking, there is a potential risk due to 
secondary hot spots that may occur along the beam path outside the focus.  This 
has been reported in the literature for different types of transducer configurations 
using similar frequencies.  The ExAblate system, with its unique, highly focused 
transducer configuration, was tested extensively using advanced simulations.  The 
results of this work showed no evidence of significant hot spots away from th e 
focal area.  In any case, the real time thermal imaging feedback samples the entire 
field of view around the targeted tumor.  These thermal images are displayed 
during the course of the energy delivery and therefore if any evidence of a 
secondary hot spot is observed, the treating physician will be able to utilize the 
ExAblate system “real -time” stop sonication button that instantaneously halts 
energy delivery.  Importantly,, the system is well equipped to handle it in real 
time and prior to incurring any tissue damage by shutting down the sonication 
prior to use of a Stop Sonication button being depressed.. 
10. Neurological risks:  Thermal “lesioning” in the brain may lead to heat transfer to 
immediately surrounding brain tissue or to hemorrhage. For a short period of time 
following the treatment, the surrounding tissue may be affected by inflammatory 
reaction. The length of the period cannot be predicted, but would be expected to resolve 
  InSightec 
 
InSightec CONFIDENTIAL   52 | P a g e  in 2-3 weeks based on our prior experience with sequential imaging in focused ultrasound 
thalamotomy for patients with Essential Tremor and tremor dominant PD. These 
mechanisms may cause transient local neurological deficits or symptoms. These 
complications are not typically permanent. If these symptoms are detected, medical 
management with dexamethasone and/or mannitol might be effective.  In severe cases, a 
craniotomy can be performed to relieve increased intracranial pressure, and permanent 
neurological deficits or death could possibly result.  
No benefit – The subject may receive no benefit from this procedure.  While ablation of the 
globus pallidus has generally been shown to be effective in motor control, there is the chance 
that it will not be effective for the subject, or that the effect may not be permanent.  Tremor is 
only one symptom of Parkinson’s Disease and relief from tremor may permit other symptoms of 
the underlying disease, such as rigidity, freezing or dyskinea, incoordination or ataxia or other 
parkinsonian symptoms, to predominate your symptoms profile after treatment.  Similarly, the 
literature shows that treatment effects may not be permanent as the disease is progressive over 
time, eventually resulting in dementia, inability to care for oneself, and death.  The subject may 
find that they will need to continue to take their medications or even increase their medications 
with time. 
6.2 Anticipated Treatment Side Effects from ExAblate 
All adverse events will be reported in the Case Report Forms (CRFs) and analyzed for their 
relationship to the treatment device, the procedure, and disease progression. Based on previous 
treatment experience, the following anticipated side effects have been identified as possible 
treatment related complications of ExAblate treatment.  These can be classified into Non-
significant and Significant Anticipated Treatment Side Effects based on their medical severity, 
additional treatments required, and long-term consequences for the subject.  
Non-significant Anticipated Treatment Side Effects of ExAblate treatment are those that 
normally resolve without sequelae within 1-14 days of the treatment: 
 minor pain from subject positioning or system interface (i.e. back pain, soreness in neck).  
 transient fever: oral temperature >100.4oF/38oC, lasting less than 24 hours 
 minor (1o or 2o) skin burns less than 2 cm in diameter 
 bruising of the skin along the treatment path 
 increase in edema surrounding the treatment area as shown on MRI.  
 headache 
 dizziness, nausea or vomiting 
Significant Anticipated Treatment Side Effects of ExAblate are those which may require medical 
treatment, may have sequelae, and for which time of resolution is not defined. The following side 
effects are thought to be improbable but their relative risk remains to be defined: 
Scalp in the sonication pathway: 
 skin burns (>2o) with ulceration of the skin 
 scar formation 
 Loss of sensation 
  InSightec 
 
InSightec CONFIDENTIAL   53 | P a g e   atrophy 
Bone in the sonication pathway: 
 bone necrosis 
Dura, venous sinuses, and cortical veins 
 subdural bleeding 
 vein thrombosis 
 seizures 
 symptoms from disturbances of eloquent cortical areas (motor, sensory, auditory, visual, 
speech) 
Other brain tissue 
 necrosis of normal tissue due to incorrect targeting 
 thermal damage to adjacent functional brain tissue (e.g.: optical tract) 
 bleeding in the treated area 
 cerebral infarction 
 neurological deficits 
 moderate or severe increase in cerebral edema as shown by MRI scans 
 symptomatic increase of intracranial pressure 
 death 
Cerebral arteries 
 bleeding 
 coagulation thrombosis 
 vasospasm 
 death 
 
The experience of Significant Anticipated Treatment Side Effects in ExAblate treatment in the 
breast and uterus have been less than 5% as shown in prior clinical experience. In brain 
treatments there is limited prior experience with the ExAblate Transcranial system and the 
probability of an adverse effect is unknown.  It is the purpose of this study to gain experience in 
pallidotomy that will allow us to evaluate the safety of ExAblate Transcranial system of 
advanced idiopathic PD (See also Section- 6.1.7 .d). 
6.3 Adverse Reactions and Precautions 
The subjects will be educated as to what to expect during the procedure and the importance of 
immediately communicating any problems, unusual symptoms, or discomfort, to the investigator 
during the treatment and throughout the follow-up period. Subjects will also be educated as to 
what sensations or perceptions could indicate that neurological damage may be starting to occur. 
They will be told to use their handheld stop sonication button if they perceive anything unusual 
may be happening so that they can be neurologically assessed. All adverse reactions occurring in 
this study will be recorded in the Case Report Forms.  Each AE will be assessed for its cause 
(i.e., categorized as definitely, probably, possibly, or unrelated to the device, procedure o r 
disease progression).  Alternative treatments resulting from post-surgical changes in neurological 
status will be captured and reported.   
  InSightec 
 
InSightec CONFIDENTIAL   54 | P a g e  6.4  Criteria for Removal from the Study 
Subjects can be withdrawn from the study at any time if, in the opinion of the principal 
investigator, it is not in the best interest of the subject to carry on as planned.  In addition, a 
subject may also chose to exit the study at any time, but will be strongly encouraged to 
participate in the follow-up visits for safety reasons (continued monitoring of subject safety).  
Subjects who opt for alternative PD treatments will be withdrawn at the time those procedures 
are performed. 
6.5 Rules for Stopping the Study 
This study may be stopped, if, in the opinion of the DSMB, serious risks to the health and 
welfare of subjects are observed that are directly related to the use of the device.  Any two (2) of 
the following scenarios would invoke this section of the protocol to stop the study until the 
DSMB and the FDA can review the events and recommend potential study modifications to 
reduce the risk.  InSightec will evaluate the cause of the safety concerns and determine relation 
of these safety events to the device, along with any possible mitigating steps to protect patients 
from device harm.  Events that could result in a study halt include any two of the following 
events: 
 Any death that is deemed to be caused by the ExAblate treatment 
 Any event of intracranial hemorrhage deemed to be caused by the ExAblate device 
 Any increase in UDRS at Month 1 as determined by the treating neurologist 
 Any increase in MDS-UPDRS Part III of more than 3 points on the treated side at Month 
1 as determined by the attending neurologist 
 Increase in MDS-UPDRS to a three or four in question 2.1 (speech), question 2.2 (saliva 
and drooling), or question 2.3 (chewing and swallowing) 
 A significant cognitive decline or significant mood/behavioral change as determined by 
the neuropsychologist. 
 A significant and unresolved neurologic impairment (ie hemiparesis or oculomotor 
deficit) noted at the Month 1 assessment 
 A significant MRI finding (ie overt cerebral hemorrhage or infarction). Some degraded 
blood products at the GPi target are expected as SWI signal. 
 A significant and unresolved neurologic impairment (ie hemiparesis or "homonyomous 
hemianopsia") noted at the Month 1 assessment 
 A significant and unresolved MRI finding (ie overt cerebral hemorrhage or infarction). 
Some degraded blood products at the GPi target are expected as SWI signal. 
Investigator(s) shall promptly report the occurrence of any such events to the Sponsor (i.e. 
InSightec) and the Sponsor shall promptly initiate review by the DSMB as well as reporting such 
event(s) to the FDA.  Once the DSMB has had an initial assessment of an event of this type, it 
may recommend stopping the study in order to investigate fully the events and circumstances.  
  InSightec 
 
InSightec CONFIDENTIAL   55 | P a g e  This will be communicated to FDA and all IRBs and sites.  With full cooperation of the treating 
investigator and the Sponsor, the DSMB will evaluate the circumstances of the event, determine 
relation of these events to the ExAblate, and whether any modifications to the protocol or the 
device must be made to improve safety.  The Sponsor will keep FDA informed of the results of 
the DSMB evaluation and of any potential actions taken by the Sponsor.  Once the review is 
completed and any mitigations are in place, and the DSMB recommends re-opening the study 
with concurrence by the FDA, then then InSightec will communicate this with all sites and their 
IRBs to begin to re-open and continue the study. 
 
6.6 Adverse Event Reporting 
It is the responsibility of the investigator to document all AE’s occurring during the course of the 
study.  At each visit, the investigator will evaluate AE’s. AE’s not previously documented in the 
study will be recorded on the Adverse Event Log within the CRF. The nature of each event, date 
and time (when appropriate) of onset, outcome, frequency, maximum intensity, action taken, 
expectedness, and causal relationship will be recorded. AEs already documented in the CRF (i.e., 
at a previous assessment) and designated as ‘ongoing’, should be reviewed at subsequent visits 
as necessary. If these have resolved, the documentation in the CRF should be completed 
including an end date for the event.  
Standard Code of Federal Regulation (CFR) definitions for Serious Adverse Events (SAEs) will 
be used for evaluation of adverse events.   
SAE  [§803.3(aa)(1)] is an injury or illness that:  
 causes death 
 is life threatening, even if temporary in nature;  
 results in permanent impairment of a body function or permanent damage to a 
body structure; or  
 necessitates medical or surgical intervention to preclude permanent impairment of a 
body function or permanent damage to a body structure.  
 
All AEs (related or unrelated) meeting the criteria for an SAE require notification of the sponsor 
and the reviewing IRB as soon as possible, with subsequent completion of additional paperwork 
provided by the sponsor fully documenting the course of the event, all treatments, and final 
outcome.  Initial reporting of an SAE should be made to the sponsor no later than two (2) 
working days after the PI learns of the incident.  AEs that do not affect the safety or overall well-
being of the subject, are mild/moderate in nature, are estimated to be temporary in duration even 
though the exact end date may not be determined a priori  (e.g., eye twitch increased from 
baseline) may be presented and discussed with DSMB to determine their final classification 
status as a serious or non-serious adverse event. 
Standard Code of Federal Regulation (CFR) definitions for Unanticipated Adverse Device 
Effects (UADEs) will be used for evaluation of this type of adverse event. 
  InSightec 
 
InSightec CONFIDENTIAL   56 | P a g e  UADE  [§812.3(s)] means any serious adverse event on health or safety or any life-
threatening problem or death caused by, or associated with, a device, if that effect, problem, or 
death was not previously identified in nature, severity, or degree of incidence in the 
investigational plan or application (including a supplementary plan or application), or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or 
welfare of subjects. 
Any UADEs will be reported to the Sponsor and to the reviewing IRB as soon as possible. 
However, in no event must this report be made later than two (2) working days after the PI learns 
of the incident.  
6.7 Data Safety Monitoring Board 
A Data Safety Monitoring Board will be used to review all AE ’s on the study at a minimum of 
annually prior to submission of the annual report to FDA. Their role is to evaluate all AE's that 
occur throughout the study and determine if they are in fact related to the ExAblate, or some 
other cause. Investigators will monitor all treatments for any AE's, and consider the following 
questions for AEs in the Test Arm: 
- Was the adverse event serious? 
- Was the adverse event life-threatening, caused a disability, required or prolonged 
hospitalization, or caused death? 
- Was the adverse event device related? 
- Was the adverse event unexpected? 
- Is there an unreasonable risk in continuing the trial? 
Adverse Events meeting all the above conditions would require reporting to the FDA, stopping 
the study pending the results of further investigation, and FDA approval to re-start the study.  
Following the DSMB review of the event, and if in the opinion of the DSMB, a modification of 
the study protocol were necessary to provide adequate protection to future study participants, the 
modification would be implemented prior to reinitiating the investigation.  Any such amendment 
would be reported to the IRB and FDA for their respective approvals to re-start the study as it is 
required by the applicable regulations. 
All adverse events will be assessed for their relationship to the study device or procedure.  
Standard Code of Federal Regulation (CFR) definitions for SAEs and UADEs will be used in 
assessment of adverse events which will be adjudicated by the DSMB.  
7 POTENTIAL BENEFITS 
There may or may not be any benefit to participating in this study.  This technique is still being 
investigated.  It may provide some therapeutic value for subjects with few or no other options 
due to surgical risk or who oppose deep brain stimulation techniques. The symptoms may 
decrease and/or the quality of life of the subject may improve due to relief of symptoms.  
  InSightec 
 
InSightec CONFIDENTIAL   57 | P a g e  However, there is no guarantee that this procedure will reduce, eliminate symptoms, or otherwise 
treat the underlying disorder.  Other subjects may benefit from this procedure in the future, if 
further trials prove it to be a safe and effective therapy.   
8 MONITORING PLAN 
Clinical Monitoring for this study will be managed by InSightec. The Clinical Monitor is 
qualified by training and experience to oversee the conduct of this study. The Clinical Monitor’s 
responsibilities include maintaining regular contact with each investigational site through 
telephone contact and on-site visits, to ensure that:  
 The trial is conducted according to FDA and GCP requirements;  
 The trial is conducted according to InSightec internal SOPs 
 The Investigational Plan is followed;  
 Complete, timely, and accurate data are submitted;  
 Problems with inconsistent or incomplete data are addressed;  
 Complications and unanticipated adverse effects are reported to the Sponsor and the IRB;  
 The site facilities will be monitored to stay adequate to meet the requirements of the 
study.  
The Clinical Monitor will initiate the Study during an on-site visit and will continue to perform 
on-site monitoring visits as frequently as deemed necessary. The first monitoring visit will 
usually be made as soon as possible after enrollment has been initiated. At this visit and all 
monitoring visits, the Clinical Monitor will compare the data entered onto the CRFs with the 
hospital or clinical records (source documents). Source documentation must be available to 
substantiate proper informed consent procedures, adherence to protocol procedures, adequate 
reporting and follow-up of AEs, and device procedure information. Findings from the review of 
CRFs and source documents during a monitoring visit will be discussed with the PI. Completed 
paper or electronic CRFs will be reviewed prior to data closure at each visit. The dates of the 
monitoring visits will be recorded in a Log to be kept at the clinical site. During monitoring 
visits, the Sponsor expects that the study coordinator and the PI will be available, the source 
documentation will be available, and a suitable environment will be provided for review of Study 
related documents.   
Sites should make every effort to contact all subjects for study follow-up to encourage visit 
compliance.  Sites should keep a log of dates of attempted contact and results. After 3 
unsuccessful attempts at contact (e.g., by telephone or email) and sending 1 certified letter to 
solicit their visit compliance a subject may be considered lost to follow-up.    
Monitoring procedures will follow the Sponsor SOPs. 
8.1 Electronic Data Capture (EDC) 
Electronic CRFs (eCRFs) will be to capture protocol-specific information during the conduct of 
this study.  This electronic data capture of the eCRFs is based on the Oracle Software system, 
and is designed, run and hosted by Sponsor (Haifa, Israel).   
  InSightec 
 
InSightec CONFIDENTIAL   58 | P a g e  9 INVESTIGATOR RESPONSIBILITIES 
The Principal Investigator will be required to sign the Investigator Agreement.  All investigators 
will undergo extensive training on the protocol and operation of the ExAblate system, and 
provide documentation of their specialized training.  
10 APPENDICES 
Appendix – A: Informed Consent 
Appendix – B: Neuropsychological Assessments 
 
  InSightec 
 
InSightec CONFIDENTIAL   59 | P a g e  REFERENCES  
1. Hely, M.A., et al., Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive 
problems dominate at 15 years.  Mov Disord, 2005. 20(2): p. 190-9. 
2. Hely, M.A., et al., The Sydney multicenter study of Parkinson's disease: the inevitability of 
dementia at 20 years.  Mov Disord, 2008. 23(6): p. 837-44. 
3. Driver, J.A., et al., Incidence and remaining lifetime risk of Parkinson disease in advanced age.  
Neurology, 2009. 72(5): p. 432-8. 
4. Khandhar, S.M. and W.J. Marks, Epidemiology of Parkinson's disease.  Dis Mon, 2007. 53(4): p. 
200-5. 
5. Riederer, P. and S. Wuketich, Time course of nigrostriatal degeneration in parkinson's disease. A 
detailed study of influential factors in human brain amine analysis.  J Neural Transm, 1976. 38(3-
4): p. 277-301. 
6. Rodriguez-Oroz, M.C., et al., Bilateral deep brain stimulation in Parkinson's disease: a 
multicentre study with 4 years follow-up.  Brain, 2005. 128(Pt 10): p. 2240-9. 
7. Deuschl, G., et al., The pathophysiology of parkinsonian tremor: a review.  J Neurol, 2000. 247 
Suppl 5 : p. V33-48. 
8. Deuschl, G., P. Bain, and M. Brin, Consensus statement of the Movement Disorder Society on 
Tremor. Ad Hoc Scientific Committee.  Mov Disord, 1998. 13 Suppl 3 : p. 2-23. 
9. Sung, Y.H., et al., Factors predicting response to dopaminergic treatment for resting tremor of 
Parkinson's disease.  Mov Disord, 2008. 23(1): p. 137-40. 
10. Ahlskog, J.E. and M.D. Muenter, Frequency of levodopa-related dyskinesias and motor 
fluctuations as estimated from the cumulative literature.  Mov Disord, 2001. 16(3): p. 448-58. 
11. Colosimo, C. and M. De Michele, Motor fluctuations in Parkinson's disease: pathophysiology 
and treatment.  Eur J Neurol, 1999. 6(1): p. 1-21. 
12. Grandas, F., M.L. Galiano, and C. Tabernero, Risk factors for levodopa-induced dyskinesias in 
Parkinson's disease.  J Neurol, 1999. 246(12): p. 1127-33. 
13. Van Gerpen, J.A., et al., Levodopa-associated dyskinesia risk among Parkinson disease patients 
in Olmsted County, Minnesota, 1976-1990.  Arch Neurol, 2006. 63(2): p. 205-9. 
14. Fahn, S., How do you treat motor complications in Parkinson's disease: Medicine, surgery, or 
both?  Ann Neurol, 2008. 64 Suppl 2 : p. S56-64. 
15. Metman, L.V. and S.T. O'Leary, Role of surgery in the treatment of motor complications.  Mov 
Disord, 2005. 20 Suppl 11 : p. S45-56. 
16. Cooper, I.S., Ligation of the anterior choroidal artery for involuntary movements; parkinsonism.  
Psychiatr Q, 1953. 27(2): p. 317-9. 
17. Cooper, I.S., Surgical occlusion of the anterior choroidal artery in parkinsonism.  Surg Gynecol 
Obstet, 1954. 92(2): p. 207-19. 
18. Spiegel, E.A. and H.T. Wycis, Pallidothalamotomy in chorea.  Arch Neurol Psychiatry, 1950. 
64(2): p. 295-6. 
19. Spiegel, E.A. and H.T. Wycis, Effect of thalamic and pallidal lesions upon involuntary 
movements in choreoathetosis.  Trans Am Neurol Assoc, 1950. 51: p. 234-7. 
20. Spiegel, E.A. and H.T. Wycis, Ansotomy in paralysis agitans.  AMA Arch Neurol Psychiatry, 
1953. 69(5): p. 652-3. 
21. Svennilson, E., et al., Treatment of parkinsonism by stereotatic thermolesions in the pallidal 
region. A clinical evaluation of 81 cases.  Acta Psychiatr Scand, 1960. 35: p. 358-77. 
22. Hassler, R., F. Mundinger, and T. Riechert, Correlations between clinical and autoptic findings 
in stereotaxic operations of parkinsonism.  Confin Neurol, 1965. 26(3): p. 282-90. 
23. Hassler, R., et al., Physiological observations in stereotaxic operations in extrapyramidal motor 
disturbances.  Brain, 1960. 83: p. 337-50. 
  InSightec 
 
InSightec CONFIDENTIAL   60 | P a g e  24. Birkmayer, W. and O. Hornykiewicz, [The L-3,4-dioxyphenylalanine (DOPA)-effect in 
Parkinson-akinesia].  Wien Klin Wochenschr, 1961. 73: p. 787-8. 
25. Laitinen, L.V., A.T. Bergenheim, and M.I. Hariz, Leksell's posteroventral pallidotomy in the 
treatment of Parkinson's disease.  J Neurosurg, 1992. 76(1): p. 53-61. 
26. De Bie, R.M., et al., Bilateral pallidotomy in Parkinson's disease: a retrospective study.  Mov 
Disord, 2002. 17(3): p. 533-8. 
27. Intemann, P.M., et al., Staged bilateral pallidotomy for treatment of Parkinson disease.  J 
Neurosurg, 2001. 94(3): p. 437-44. 
28. York, M.K., et al., Short and long-term motor and cognitive outcome of staged bilateral 
pallidotomy: a retrospective analysis.  Acta Neurochir (Wien), 2007. 149(9): p. 857-66; 
discussion 866. 
29. Mazars, G., L. Merienne, and C. Cioloca, Control of dyskinesias due to sensory deafferentation 
by means of thalamic stimulation.  Acta Neurochir Suppl (Wien), 1980. 30: p. 239-43. 
30. Benabid, A.L., et al., Long-term suppression of tremor by chronic stimulation of the ventral 
intermediate thalamic nucleus.  Lancet, 1991. 337(8738): p. 403-6. 
31. Siegfried, J. and B. Lippitz, Bilateral chronic electrostimulation of ventroposterolateral 
pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms.  Neurosurgery, 
1994. 35(6): p. 1126-9; discussion 1129-30. 
32. Blomstedt, P., G.M. Hariz, and M.I. Hariz, Pallidotomy versus pallidal stimulation.  Parkinsonism 
Relat Disord, 2006. 12(5): p. 296-301. 
33. Kumar, R., et al., Pallidotomy and deep brain stimulation of the pallidum and subthalamic 
nucleus in advanced Parkinson's disease.  Mov Disord, 1998. 13 Suppl 1 : p. 73-82. 
34. Bergman, H., T. Wichmann, and M.R. DeLong, Reversal of experimental parkinsonism by lesions 
of the subthalamic nucleus.  Science, 1990. 249(4975): p. 1436-8. 
35. DeLong, M.R., Primate models of movement disorders of basal ganglia origin.  Trends Neurosci, 
1990. 13(7): p. 281-5. 
36. DeLong, M.R., M.D. Crutcher, and A.P. Georgopoulos, Primate globus pallidus and subthalamic 
nucleus: functional organization.  J Neurophysiol, 1985. 53(2): p. 530-43. 
37. Aziz, T.Z., et al., Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-exposed primate.  Br J Neurosurg, 1992. 6(6): p. 575-82. 
38. Brotchie, J.M., et al., Alleviation of parkinsonism by antagonism of excitatory amino acid 
transmission in the medial segment of the globus pallidus in rat and primate.  Mov Disord, 1991. 
6(2): p. 133-8. 
39. Guridi, J., et al., Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical 
analysis.  Brain, 1996. 119 ( Pt 5) : p. 1717-27. 
40. Wichmann, T. and M.R. DeLong, Functional and pathophysiological models of the basal 
ganglia.  Curr Opin Neurobiol, 1996. 6(6): p. 751-8. 
41. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in 
Parkinson's disease.  N Engl J Med, 2001. 345(13): p. 956-63. 
42. Benabid, A.L., et al., Acute and long-term effects of subthalamic nucleus stimulation in 
Parkinson's disease.  Stereotact Funct Neurosurg, 1994. 62(1-4): p. 76-84. 
43. Esselink, R.A., et al., Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in 
Parkinson's disease: one year follow-up of a randomised observer-blind multi centre trial.  Acta 
Neurochir (Wien), 2006. 148(12): p. 1247-55; discussion 1255. 
44. Anderson, V.C., et al., Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson 
disease.  Arch Neurol, 2005. 62(4): p. 554-60. 
45. Burchiel, K.J., et al., Comparison of pallidal and subthalamic nucleus deep brain stimulation for 
advanced Parkinson's disease: results of a randomized, blinded pilot study.  Neurosurgery, 1999. 
45(6): p. 1375-82; discussion 1382-4. 
  InSightec 
 
InSightec CONFIDENTIAL   61 | P a g e  46. Nakamura, K., et al., Effects of unilateral subthalamic and pallidal deep brain stimulation on fine 
motor functions in Parkinson's disease.  Mov Disord, 2007. 22(5): p. 619-26. 
47. Hariz, M.I., et al., Multicenter study on deep brain stimulation in Parkinson's disease: an 
independent assessment of reported adverse events at 4 years.  Mov Disord, 2008. 23(3): p. 416-
21. 
48. York, M.K., et al., Cognitive declines following bilateral subthalamic nucleus deep brain 
stimulation for the treatment of Parkinson's disease.  J Neurol Neurosurg Psychiatry, 2008. 79(7): 
p. 789-95. 
49. Vitek, J.L., et al., Randomized trial of pallidotomy versus medical therapy for Parkinson's 
disease.  Ann Neurol, 2003. 53(5): p. 558-69. 
50. de Bie, R.M., et al., Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, 
multicentre trial.  Lancet, 1999. 354(9191): p. 1665-9. 
51. Weaver, F.M., et al., Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-
month outcomes.  Neurology. 79(1): p. 55-65. 
52. Okun, M.S. and K.D. Foote, Setting realistic expectations for DBS in dystonia.  Lancet Neurol. 
11(12): p. 1014-5. 
53. Alvarez, L., et al., Bilateral subthalamotomy in Parkinson's disease: initial and long-term 
response.  Brain, 2005. 128(Pt 3): p. 570-83. 
54. Tasker, R.R., Deep brain stimulation is preferable to thalamotomy for tremor suppression.  Surg 
Neurol, 1998. 49(2): p. 145-53; discussion 153-4. 
55. Schuurman, P.R., et al., A comparison of continuous thalamic stimulation and thalamotomy for 
suppression of severe tremor.  N Engl J Med, 2000. 342(7): p. 461-8. 
56. Pahwa, R., et al., Comparison of thalamotomy to deep brain stimulation of the thalamus in 
essential tremor.  Mov Disord, 2001. 16(1): p. 140-3. 
57. Anderson, V.C., et al., A randomized comparison of thalamic stimulation and lesion on self-
paced finger movement in essential tremor.  Neurosci Lett, 2009. 462(2): p. 166-70. 
58. Merello, M., Subthalamic stimulation contralateral to a previous pallidotomy: an erroneous 
indication?  Mov Disord, 1999. 14(5): p. 890. 
59. Gross, R.E., What happened to posteroventral pallidotomy for Parkinson's disease and dystonia?  
Neurotherapeutics, 2008. 5(2): p. 281-93. 
60. Okun, M.S. and J.L. Vitek, Lesion therapy for Parkinson's disease and other movement 
disorders: update and controversies.  Mov Disord, 2004. 19(4): p. 375-89. 
61. Merello, M., et al., Unilateral radiofrequency lesion versus electrostimulation of posteroventral 
pallidum: a prospective randomized comparison.  Mov Disord, 1999. 14(1): p. 50-6. 
62. Clement, G.T. and K. Hynynen, A non-invasive method for focusing ultrasound through the 
human skull.  Physics in Medicine & Biology, 2002. 47(8): p. 1219-36. 
63. Clement, G.T., et al., A magnetic resonance imaging-compatible, large-scale array for trans-skull 
ultrasound surgery and therapy.  Journal of Ultrasound in Medicine, 2005. 24(8): p. 1117-25. 
64. Hynynen, K., et al., Pre-clinical testing of a phased array ultrasound system for MRI-guided 
noninvasive surgery of the brain --a primate study.  European Journal of Radiology, 2006. 59(2): 
p. 149-56. 
65. Benabid, A.L., et al., Long-term electrical inhibition of deep brain targets in movement disorders.  
Mov Disord, 1998. 13 Suppl 3 : p. 119-25. 
66. Hynynen, K. and F.A. Jolesz, Demonstration of potential noninvasive ultrasound brain therapy 
through an intact skull.  Ultrasound in Medicine & Biology, 1998. 24(2): p. 275-83. 
67. Cline, H.E., et al., Magnetic resonance-guided thermal surgery.  Magn Reson Med, 1993. 30(1): 
p. 98-106. 
68. McDannold, N., et al., MRI investigation of the threshold for thermally induced blood-brain 
barrier disruption and brain tissue damage in the rabbit brain.  Magn Reson Med, 2004. 51(5): p. 
913-23. 
  InSightec 
 
InSightec CONFIDENTIAL   62 | P a g e  69. Cohen, Z.R., et al., Magnetic resonance imaging-guided focused ultrasound for thermal ablation 
in the brain: a feasibility study in a swine model.  Neurosurgery, 2007. 60(4): p. 593-600; 
discussion 600. 
70. Ram, Z., et al., Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain 
tumor therapy.  Neurosurgery, 2006. 59(5): p. 949-55; discussion 955-6. 
71. McDannold, N., et al., Transcranial magnetic resonance imaging- guided focused ultrasound 
surgery of brain tumors: initial findings in 3 patients.  Neurosurgery, 2010. 66(2): p. 323-32; 
discussion 332. 
72. Martin, E., et al., High-intensity focused ultrasound for noninvasive functional neurosurgery.  Ann 
Neurol, 2009. 66(6): p. 858-61. 
73. Jolesz, F.A., A.R. Bleier, and R.S. Lauter, Laser surgery benefits from guidance by MR.  Diagn 
Imaging (San Franc), 1990. 12(9): p. 103-8. 
74. Jolesz, F.A. and S.M. Blumenfeld, Interventional use of magnetic resonance imaging.  Magn 
Reson Q, 1994. 10(2): p. 85-96. 
75. Jolesz, F.A. and N. McDannold, Current status and future potential of MRI-guided focused 
ultrasound surgery.  Journal of Magnetic Resonance Imaging, 2008. 27(2): p. 391-9. 
76. Jolesz, F.A., et al., Response to and control of destructive energy by magnetic resonance.  Invest 
Radiol, 1989. 24(12): p. 1024-7. 
77. Moonen, C.T., et al., Thermal therapies in interventional MR imaging. Focused ultrasound.  
Neuroimaging Clinics of North America. 11(4): p. 737-47. 
78. Salomir, R., et al., Image-based control of the magnetic resonance imaging-guided focused 
ultrasound thermotherapy.  Topics in Magnetic Resonance Imaging, 2006. 17(3): p. 139-51. 
79. Cline, H.E., et al., MR-guided focused ultrasound surgery.  J Comput Assist Tomogr, 1992. 16(6): 
p. 956-65. 
80. Hynynen, K., et al., Noninvasive mr imaging-guided focal opening of the blood-brain barrier in 
rabbits.  Radiology, 2001. 220(3): p. 640-6. 
81. Hynynen, K., et al., MR imaging-guided focused ultrasound surgery of fibroadenomas in the 
breast: a feasibility study.  Radiology, 2001. 219(1): p. 176-85. 
82. Cline, H.E., et al., Focused US system for MR imaging-guided tumor ablation.  Radiology, 1995. 
194(3): p. 731-7. 
83. Hynynen, K., et al., MRI-guided noninvasive ultrasound surgery.  Med Phys, 1993. 20(1): p. 107-
15. 
84. Fox, S.H., et al., The Movement Disorder Society Evidence-Based Medicine Review Update: 
Treatments for the motor symptoms of Parkinson's disease.  Mov Disord. 26 Suppl 3 : p. S2-41. 
85. White, D.N., Neurosonology pioneers.  Ultrasound Med Biol, 1988. 14(7): p. 541-61. 
86. Aaslid, R., T.M. Markwalder, and H. Nornes, Noninvasive transcranial Doppler ultrasound 
recording of flow velocity in basal cerebral arteries.  J Neurosurg, 1982. 57(6): p. 769-74. 
87. Fry, W.J., et al., Production of focal destructive lesions in the central nervous system with 
ultrasound.  J. Neurosurg, 1954. 11: p. 471-478. 
88. Fry, W.J., et al., Ultrasonically produced localized selective lesions in the central nervous system.  
Am. J. Phys. Med, 1955. 34: p. 413-423. 
89. Lele, P.P., Production of deep focal lesions by focused ultrasound --current status.  Ultrasonics, 
1967. 5: p. 105-12. 
90. Fry, F.J., et al., Threshold ultrasonic dosages for structural changes in the mammalian brain.  J 
Acoust Soc Am, 1970. 48(6): p. Suppl 2:1413+. 
91. Fry, F.J. and J.E. Barger, Acoustical properties of the human skull.  J Acoust Soc Am, 1978. 
63(5): p. 1576-90. 
92. Fry, F.J., S.A. Goss, and J.T. Patrick, Transkull focal lesions in cat brain produced by ultrasound.  
Journal of Neurosurgery, 1981. 54(5): p. 659-63. 
  InSightec 
 
InSightec CONFIDENTIAL   63 | P a g e  93. Lynn, J.G., et al., A new method for the generation and use of focused ultrasound in experimental 
biology.  J. Gen. Physiol., 1942. 26: p. 179-193. 
94. Smith, S.W., et al., Some Advances in Acoustic imaging through Skull.  Symposium on Biological 
Effects, 1997: p. 37-52. 
95. Guthkelch, A.N., et al., Treatment of malignant brain tumors with focused ultrasound 
hyperthermia and radiation: results of a phase I trial.  J Neurooncol, 1991. 10(3): p. 271-84. 
96. Clement, G.T., et al., A hemisphere array for non-invasive ultrasound brain therapy and surgery.  
Phys Med Biol, 2000. 45(12): p. 3707-19. 
97. Clement, G.T., J. White, and K. Hynynen, Investigation of a large-area phased array for focused 
ultrasound surgery through the skull.  Phys Med Biol, 2000. 45(4): p. 1071-83. 
98. Vykhodtseva, N., et al., MRI detection of the thermal effects of focused ultrasound on the brain.  
Ultrasound Med Biol, 2000. 26(5): p. 871-80. 
99. Sansur, C.A., et al., Incidence of symptomatic hemorrhage after stereotactic electrode placement.  
J Neurosurg, 2007. 107(5): p. 998-1003. 
100. Deogaonkar, M., et al., Clinical problem solving: finding the target.  Neurosurgery, 2007. 61(4): 
p. 815-24; discussion 824- 5. 
101. Elias, W.J., K.M. Fu, and R.C. Frysinger, Cortical and subcortical brain shift during stereotactic 
procedures.  J Neurosurg, 2007. 107(5): p. 983-8. 
102. Xiaowu, H., et al., Risks of intracranial hemorrhage in patients with Parkinson's disease 
receiving deep brain stimulation and ablation.  Parkinsonism Relat Disord. 16(2): p. 96-100. 
103. Jagannathan, J., et al., High-Intensity Focused Ultrasound Surgery of the Brain: Part 1-a 
Historical Perspective with Modern Applications.  Neurosurgery, 2009. 64(2): p. 201-211. 
104. de Bie, R.M., et al., Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort 
study of 32 patients.  J Neurol Neurosurg Psychiatry, 2001. 71(3): p. 375-82. 
105. Eskandar, E.N., et al., Stereotactic pallidotomy performed without using microelectrode guidance 
in patients with Parkinson's disease: surgical technique and 2-year results.  J Neurosurg, 2000. 
92(3): p. 375-83. 
106. Fine, J., et al., Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease.  N 
Engl J Med, 2000. 342(23): p. 1708-14. 
107. Giller, C.A., et al., Stereotactic pallidotomy and thalamotomy using individual variations of 
anatomic landmarks for localization.  Neurosurgery, 1998. 42(1): p. 56-62; discussion 62-5. 
108. Kondziolka, D., et al., Outcomes after stereotactically guided pallidotomy for advanced 
Parkinson's disease.  J Neurosurg, 1999. 90(2): p. 197-202. 
109. Kopyov, O., et al., Microelectrode-guided posteroventral medial radiofrequency pallidotomy for 
Parkinson's disease.  J Neurosurg, 1997. 87(1): p. 52-9. 
110. Lai, E.C., et al., Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's 
disease.  Neurology, 2000. 55(8): p. 1218-22. 
111. Masterman, D., et al., Motor, cognitive, and behavioral performance following unilateral 
ventroposterior pallidotomy for Parkinson disease.  Arch Neurol, 1998. 55(9): p. 1201-8. 
112. Melnick, M.E., et al., Effect of pallidotomy on postural control and motor function in Parkinson 
disease.  Arch Neurol, 1999. 56(11): p. 1361-5. 
113. Uitti, R.J., R.E. Wharen, Jr., and M.F. Turk, Efficacy of levodopa therapy on motor function after 
posteroventral pallidotomy for Parkinson's disease.  Neurology, 1998. 51(6): p. 1755-7. 
114. Hariz, M.I. and A.T. Bergenheim, A 10-year follow-up review of patients who underwent 
Leksell's posteroventral pallidotomy for Parkinson disease.  J Neurosurg, 2001. 94(4): p. 552-8. 
115. Gianfelice, D., et al., MR imaging-guided focused US ablation of breast cancer: histopathologic 
assessment of effectiveness -- initial experience.  Radiology, 2003. 227(3): p. 849-55. 
116. Gianfelice, D., et al., MR imaging-guided focused ultrasound surgery of breast cancer: 
correlation of dynamic contrast-enhanced MRI with histopathologic findings.  Breast Cancer Res 
Treat, 2003. 82(2): p. 93-101. 
  InSightec 
 
InSightec CONFIDENTIAL   64 | P a g e  117. Gianfelice, D., et al., Feasibility of magnetic resonance imaging-guided focused ultrasound 
surgery as an adjunct to tamoxifen therapy in high-risk surgical patients with breast carcinoma.  J 
Vasc Interv Radiol, 2003. 14(10): p. 1275-82. 
118. Gianfelice, D., et al., Palliative treatment of painful bone metastases with MR imaging --guided 
focused ultrasound.  Radiology, 2008. 249(1): p. 355-63. 
119. Elias, W.J., et al., A pilot study of focused ultrasound thalamotomy for essential tremor.  N Engl J 
Med. 369(7): p. 640-8. 
120. Goetz, C.G., et al., Movement Disorder Society-sponsored revision of the Unified Parkinson's 
Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.  Mov 
Disord, 2008. 23(15): p. 2129-70. 
121. Kirby, R.S., J.M. Fitzpatrick, and J. Irani, Prostate cancer diagnosis in the new millennium: 
strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of 
prostate cancer gene 3 (PCA3).  BJU Int, 2009. 103(4): p. 441-5. 
122. McDannold, et al., MRI evaluation of thermal ablation of tumors with focused ultrasound.  J 
Magn Reson Imaging, 1998. 8(1): p. 91-100. 
 
 
  InSightec 
 
InSightec CONFIDENTIAL   65 | P a g e  Appendix A – Informed Consent Form
  InSightec 
 
InSightec CONFIDENTIAL   66 | P a g e  Appendix B - NEUROPSYCHOLOGICAL ASSESSMENTS 
It is important to screen subjects prior to treatment and to assess subjects post-treatment for 
potential cognitive and psychological effects of the treatment.  Our standard neuropsychological 
assessments will be used in the screening and cognitive assessment of PD subjects considering 
DBS surgery at the University of Virginia.  This battery of tests is designed to test the major 
domains of cognitive function with a particular emphasis on the mental functions that are most 
affected in PD.   These measures, administered by a neuropsychologist specializing in 
neurodegenerative diseases, will be obtained at Baseline and again at Month 3 post-treatment to 
determine any potential cognitive change resulting from the unilateral MRgFUS GPi 
pallidotomy.  Additionally, the battery will be implemented again at Month 12 post-treatment to 
assess for any improvement in potential deficits observed at the Month 3 time point.   
Estimated Baseline Intellectual Functioning: 
Wechsler Test of Adult Reading (WTAR)  
Mental Status: 
Montreal Cognitive Assessment (MoCA) 
Language : 
o Action fluency 
o Phonemic fluency  
o Animal Naming 
Visuospatial Functioning : 
o Rey Complex Figure Test- Copy portion 
o Wechsler Adult Intelligent Scale-4th Edition (WAIS-IV Block Design or Matrix 
Reasoning) 
Learning and Memory : 
o Hopkins Verbal learning Test-Revised (HVLT- R) 
o Brief Visuospatial Memory Test-Revised (BVMT- R) 
o Logical Memory from the Wechsler Memory Scale – Third Edition (WMS-III)) 
Attention, Working Memory, & Processing Speed : 
o Wechsler Adult Intelligent Scale-4th Edition (WAIS-IV Digit Span)  
o Trails A & B 
o Symbol-Digit Modalities Test  
o Stroop Color-Word Test 
Executive Functioning : 
o Wisconsin Card Sorting Test (WCST) 
  InSightec 
 
InSightec CONFIDENTIAL   67 | P a g e  Motor Functioning : 
o Grooved Pegboard 
Mood and Behavior : 
o Beck Depression Inventory-II (BDI-II) 
o Parkinson’s Disease Questionnaire -39 (PDQ-39) 
o Frontal Systems Behavior Scale (FrSBe) 
o Beck Anxiety Inventory (BAI) 
 